CORPORATE NEWS YEAR 2021 Evotec and EQRx announce integrated drug discovery and development partnership Hamburg, Germany, November 18, 2021 Evotec SE and EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx’s pipeline expansion efforts by leveraging Evotec’s unique data-driven, fully integrated R&D-platform, applied across different drug modalities and therapeutic areas. This approach aims to expedite the invention and development of novel drugs and helps ensure superior translation from research ideas to safe and efficacious medicines. Evotec announces the exercise of the Greenshoe option Hamburg, Germany, November 16, 2021 Evotec SE today announced that BofA Securities and Morgan Stanley, as representatives of the several underwriters, notified Evotec of the underwriters’ exercise of their option to purchase up to 3,000,000 additional ADSs, representing 1,500,000 ordinary shares at the offering price of $ 21.75 per ADS. Evotec SE reports results for the first nine months 2021 and provides corporate update Hamburg, Germany, November 11, 2021 Evotec SE today announced the financial results and corporate updates for the first nine months 2021: Strong operational performance leads to significant revenue growth; co-owned pipeline gaining momentum; J.POD® Redmond (US) operational; successful Public Offering at NASDAQ (after period-end); guidance for full-year 2021 confirmed; webcast and conference Call today at 02.00 PM CET Evotec reaches programme designations in neuroscience collaboration with Bristol Myers Squibb Hamburg, Germany, November 10, 2021 Evotec SE announced today that the Company reached additional programme designations within its neuroscience collaboration with Bristol Myers Squibb triggering payments of in total US$ 40 m to Evotec. Evotec SE announces closing of public offering Hamburg, Germany, November 9, 2021 Evotec SE announced today the closing of its public offering on 08 November 2021 in the United States of 20,000,000 American Depositary Shares (“ADSs”). Each ADS represents half of one ordinary share of Evotec. All ADSs sold in the offering were offered by Evotec at a public offering price of $ 21.75 per ADS. Evotec SE to announce results for the first nine months 2021 on 11 November 2021 Hamburg, November 3, 2021 Evotec SE will announce its financial results for the first nine months 2021 on Thursday, 11 November 2021. Evotec announces first funded projects of translational BRIDGE beLAB1407 in collaboration with Bristol Myers Squibb Hamburg, Germany, October 27, 2021 Evotec SE today announced the first two projects to be developed within beLAB1407, a collaboration between Evotec and Bristol Myers Squibb to accelerate translational research from the UK's academic life science ecosystem. Only six months after signing the beLAB1407 collaboration agreement in May 2021, the first projects to be developed within this academic BRIDGE collaboration have now been identified. Evotec SE: Translational BRIDGE beLAB2122 in collaboration with Bristol Myers Squibb identifies first project Hamburg, Germany, October 27, 2021 Evotec SE today announced the first project to be developed within beLAB2122, a collaboration between Evotec and Bristol Myers Squibb. beLAB2122 aims to bring together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects. After signing the beLAB2122 collaboration agreement in April 2021, the first project to be developed within this academic BRIDGE collaboration has now been nominated. Evotec provides preliminary nine month financial results Hamburg, Germany, October 26, 2021 Evotec SE, today reported preliminary and unaudited results for the first nine months ended 30 September 2021. Evotec SE announces launch of public offering of American Depositary Shares Hamburg, Germany, October 26, 2021 Evotec SE announced today that it has commenced a public offering in the United States of up to 22,000,000 American Depositary Shares (“ADSs”) representing 11,000,000 of its ordinary shares pursuant to a registration statement on Form F-1, as amended, filed with the U.S. Securities and Exchange Commission (“SEC”). Evotec expects to grant the underwriters a 30-day option to purchase up to an additional 3,300,000 ADSs. The sale of the ADSs and the issuance of the underlying ordinary shares will be made under exclusion of shareholders pre-emptive rights based on Evotec’s existing authorized capital. Evotec has applied to list its ADSs on the Nasdaq Global Select Market under the symbol “EVO”. Evotec SE files registration statement for proposed offering of American Depositary Shares Hamburg, Germany, October 11, 2021 Evotec SE announced today that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed offering and sale in the United States of shares of Evotec represented by American Depositary Shares (“ADSs”). The Registration Statement has not yet become effective and the final number of ADSs to be offered and their price have not yet been determined. Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type Hamburg, Germany, October 8, 2021 Evotec SE announced today that its collaboration with Bristol Myers Squibb has been expanded to include a new cell type, triggering a payment of $ 9.0 m to Evotec. Evotec publishes DDup 11 – AI-driven antibody discovery at Evotec Hamburg, Germany, September 15, 2021 The 11th edition is dedicated to our exciting new capabilities in the biologics lane of Evotec’s “Multi-modality Autobahn.” Evotec partner Bayer: Phase IIb trial shows eliapixant significantly decreases cough frequency in patients with refractory chronic cough Berlin, Germany, September 6, 2021 Evotec partner Bayer today reported more detailed results from PAGANINI, the Phase IIb dose-finding study evaluating the efficacy and safety of eliapixant in patients with refractory chronic cough (“RCC”). Eliapixant (BAY1817080) is an investigational orally administered, potent and selective P2X3 receptor antagonist derived from a former multi-target research collaboration between Bayer and Evotec. Evotec announces Bristol Myers Squibb opt-in of EVT8683 as the first programme from iPSC-based neurodegeneration collaboration Hamburg, Germany, September 2, 2021 Evotec SE announced today that Bristol Myers Squibb Company has exercised its option to enter into an exclusive global license for EVT8683 which comes from a broader neurodegeneration collaboration. EVT8683 is a small molecule targeting a key cellular stress response that holds great promise in various neurodegenerative indications and is ready to enter clinical development. The programme originated from a phenotypic screening approach based on Evotec’s leading iPSC platform and reached IND filing within only 5 years. Under an option agreement with Celgene (which is now a Bristol Myers Squibb company), Bristol Myers Squibb has rights to additional programmes in neurodegenerative diseases. Evotec partner Kazia Therapeutics announces full regulatory approval for Phase I study of EVT801 Sydney, Australia, September 2, 2021 Evotec partner Kazia Therapeutics Limited today announced that the planned phase I study for EVT801 has received full approval from L’Agence Nationale de Sécurité du Médicament et des Produits de Santé (“ANSM”), the French regulatory agency. The study is expected to open to recruitment by the end of CY2021. Evotec and Secarna Pharmaceuticals expand strategic partnership in the field of antisense drug discovery Munich/Martinsried and Hamburg, Germany, September 2, 2021 Evotec SE and Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide ("ASO") therapies to address challenging or previously undruggable targets via its LNAplus™ platform, have expanded their strategic partnership in the field of ASO-based therapeutics. Evotec SE reports first half-year 2021 results and corporate updates Hamburg, Germany, August 11, 2021 Evotec SE today announced its financial results for the first half-year of 2021: Strong overall performance in the first half of 2021 gaining speed; rapid capacity build-up to foster undisputed growth and future margin expansion; registration statement for proposed offering of American Depositary Shares submitted; guidance for full-year 2021 confirmed; webcast and conference call today at 2.00 pm CEST Just - Evotec Biologics opens J.POD® 1 US in Redmond, Washington Hamburg, Germany, August 11, 2021 Evotec SE today announced the opening of the company’s late-stage clinical and commercial biologics cGMP manufacturing facility (J.POD® 1 US) in Redmond, Washington. The innovative cGMP biomanufacturing facility is the final step in Just – Evotec Biologics’ J.DESIGN platform that integrates data analytics and machine learning through all activities involved with the discovery, development, and manufacture of biologics. This includes design of discovery libraries (J.DISCOVERY™), molecules (J.MD™), processes (JP3®) and the manufacturing facility, J.POD®. Evotec spin-off Topas Therapeutics extends Series B, raising total of € 40 m (~$ 48 m) in this round Hamburg, Germany, July 29, 2021 Evotec spin-off company Topas Therapeutics GmbH ("Topas"), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today announced that the Company has successfully extended its Series B round with an additional € 18 m (~$ 22 m) raised, bringing the total for this financing to € 40 m. All of Topas’ existing investors participated in the extension. Evotec creates long-term growth opportunities by initiating “Campus Levi-Montalcini” in Verona Hamburg, Germany, July 1, 2021 Evotec SE today announced that Evotec has added significant opportunities for further, long-term growth by acquiring the Verona site from GlaxoSmithKline SpA. During a site meeting, the employees also decided on a new name for their campus. In commemoration of Italian Nobel laureate Rita Levi-Montalcini, the Verona site will be named “Campus Levi-Montalcini” going forward. Evotec launches “PRROTECT”, a pre-competitive initiative to be better prepared for future pandemics Hamburg, Germany, June 15, 2021 Evotec SE announced today that the Company has launched an initiative for pandemic preparedness (“PRROTECT”). PRROTECT leverages a comprehensive set of novel projects and technologies to be better prepared for and respond faster to viral pandemics of the future. Evotec SE Virtual Annual General Meeting 2021 approves all proposed agenda items Hamburg, Germany, June 15, 2021 Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s virtual Annual General Meeting 2021 with the required majority. Due to the COVID-19 pandemic, this year’s Annual General Meeting again was held as a purely virtual event. Evotec partners with CEBINA to launch Danube Labs, a partnership to develop cutting edge biotechnology projects sourced from Central and Eastern European Universities and Research Institutions Vienna, Austria, June 14, 2021 CEBINA GmbH today announces the launch of Danube Labs, a partnership with Evotec SE to fast-track early-stage academic research to drug discovery and development. The joint project, financed by a dedicated group of private investors, will identify, and develop academic projects into mature therapeutic product development opportunities, primed for biotech company formation or partnering. Autobahn Labs incubator announces partnership with Cold Spring Harbor Laboratory to advance novel science to the clinic Palo Alto, CA, USA, June 7, 2021 Autobahn Labs, an early-stage drug discovery incubator, today announced a new strategic venture collaboration with Cold Spring Harbor Laboratory (CSHL). Together with Autobahn Labs, CSHL will identify promising research programs with therapeutic potential and partner to form promising new drug discovery companies. Evotec SE reports results for the first quarter 2021 and provides corporate update Hamburg, Germany, May 11, 2021 Evotec SE today announced the financial results and corporate updates for the first quarter 2021. Group revenues from contracts with customers increased by 11% to € 133.1 m (Q1 2020: € 119.4 m); Base business growth of 28%, adjusted for the end of the Sanofi payment (since April 2020) and unfavourable fx effects; EVT Execute revenue growth of 16% (11% adjusted for material recharges) to € 136.9 m (Q1 2020: € 118.2 m), EVT Innovate revenues up 21% (20% adjusted for material recharges) to € 28.2 m (Q1 2020: € 23.3 m) Evotec launches "beLAB1407" to accelerate translational research from the UK's academic life science ecosystem in collaboration with Bristol Myers Squibb Hamburg, Germany, May 6, 2021 Evotec SE announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of Evotec’s drug discovery and development platforms and early-stage therapeutic concepts from the Universities of Birmingham, Edinburgh, Nottingham, and Dundee, beLAB1407 offers a unique route to the advancement of first-in-class therapeutics and the creation of spin-out companies. Evotec and the GCKD study enter into strategic collaboration to build a unique molecular patient database Hamburg and Erlangen, Germany, May 4, 2021 Evotec SE and the University Hospital Erlangen today announced a partnership regarding molecular analyses of biospecimens from the German Chronic Kidney Disease (“GCKD”) cohort study. Under the agreement, the research team will make use of Evotec’s proprietary EVOpanOmics and EVOpanHunter platforms to facilitate deep molecular profiling of patient samples. The Evotec platforms combine enhanced throughput proteomics, high-throughput transcriptomics and integrated data analysis. Evotec SE to announce results for the first quarter 2021 on 11 May 2021 Hamburg, Germany, May 4, 2021 Evotec SE will announce its financial results for the first quarter of 2021 on Tuesday, 11 May 2021. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. Bristol Myers Squibb exercises option to extend targeted protein degradation partnership with Evotec Hamburg, Germany, April 26, 2021 Evotec SE today announced that Bristol Myers Squibb has decided to exercise their option to extend its partnership with Evotec in the field of targeted protein degradation. Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated this strategic drug discovery and development partnership in 2018 with the goal to identify first-in-class drug candidates initially focusing on solid tumours. Evotec invests into Oxford Cell Therapy Company "OxVax" Hamburg, Germany, April 21, 2021 Evotec SE announced today that the Company has invested into OxVax, a new immuno-oncology company based on research from Oxford University, which enables the development of the next generation of cancer vaccines with the potential to overcome the limitations of the current approaches. Evotec accelerates access to biologic therapeutics with initiation of manufacturing facility in Toulouse Hamburg, Germany, April 20, 2021 Evotec SE today announced that the Company has initiated the construction of its J.POD® 2 EU biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® 2 EU, Evotec’s second innovative cGMP biomanufacturing facility, will employ Just – Evotec Biologics’ cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations housed inside autonomous cleanrooms. Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 Hamburg, Germany, April 19, 2021 Evotec SE announced today that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec’s oncology project EVT801. Evotec launches “beLAB2122”, translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb Hamburg, Germany, April 13, 2021 Evotec SE announced today that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company. beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects. Evotec and Exscientia announce start of human clinical trials of novel immuno-oncology drug Hamburg, Germany, April 9, 2021 Evotec SE today announced the most advanced asset arising from their joint venture with Exscientia has entered human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed between Exscientia and Evotec, including application of Exscientia’s next generation 3-D evolutionary AI-design platform, Centaur Chemist®. The drug candidate has potential for best-in-class characteristics, with high selectivity for the target receptor, bringing together potential benefits of reduced systemic side effects as well as minimal brain exposure to avoid potential undesired centrally-mediated side effects. The Science Pool: Evotec’s New Scientific Content Hub Hamburg, Germany, March 26, 2021 Knowledge sharing within the scientific community is a key focus for Evotec. Sharing resources will help to collectively advance R&D and accelerate innovation - ultimately leading to new technology and therapies reaching the market faster. Evotec SE fiscal year 2020 results: Gaining speed on the "data-driven R&D Autobahn to Cures" Hamburg, Germany, March 25, 2021 Very strong financial results: 12% increase in Group revenues beating guidance despite pandemic; unique innovation platforms and infrastructure support long-term growth in all modalities; solid balance sheet, strong foundation for next expansion steps Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance Hamburg, Germany, March 22, 2021 Evotec SE today announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches. Evotec SE to announce results for fiscal year 2020 on 25 March 2021 Hamburg, Germany, March 18, 2021 Evotec SE will announce its financial results for 2020 on Thursday, 25 March 2021. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. CMO Leadership Awards 2021 Hamburg, Germany, March 18, 2021 Evotec announces that the Company has been selected as a winner of a 2021 CMO Leadership Award in the categories Compatibility (Big Pharma), Expertise (Big Pharma), and Service (Overall, Small Pharma) G-CON Manufacturing and Just – Evotec Biologics Complete the Installation of Cleanroom PODs® for the First J.POD® Facility in North America College Station, Texas, and Redmond, Washington, USA, March 16, 2021 Just – Evotec Biologics’ Redmond, Washington site offers true meaning to “Facility of the Future” with flexible and podular manufacturing of clinical and commercial-stage biologics. Argobio announces its launch with 50 M€ to create and develop pioneering biotech spinouts with the support of Bpifrance, Kurma Partners, Angelini Pharma, Evotec, and the Institut Pasteur Paris, France, March 2, 2021 Argobio SAS, a newly-created start-up studio dedicated to life sciences, today announced its launch with 50 M€ of committed capital. Argobio was initiated by Kurma Partners, a leading Paris and Munich-based healthcare venture capital firm, and Bpifrance, the French national investment bank. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, internationally renowned center for biomedical research. Evotec and Chinook Therapeutics enter into strategic collaboration to discover and develop novel precision medicines for chronic kidney diseases Hamburg, Germany, March 1, 2021 Evotec SE and Chinook Therapeutics, Inc. today announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases (“CKD”). Based on Evotec’s proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterise and validate novel mechanisms and discover and develop precision medicines. Evotec and Related Sciences enter integrated drug discovery and development partnership Hamburg, Germany, February 9, 2021 Evotec SE announced today that the Company has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period. Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure Hamburg, Germany, February 4, 2021 Evotec SE today announced that the Company has entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf (“UKE”) for the development of a highly innovative first-in-class cell therapy approach for the treatment of heart failure. Evotec Statement on COVID-19 Hamburg, Germany, February 1, 2021 Many of you have been asking us about the Coronavirus and its potential impact on Evotec and its affiliates. At Evotec, we are actively managing our operations to maintain business continuity while taking measures to protect the health and wellbeing of our employees, their families and the local communities in which they live and work. We have taken a number of steps to ensure the continued health and safety of our colleagues and prepare our business during this challenging time. Evotec CSO Cord Dohrmann Appointed to German Council of Science and Humanities Hamburg, Germany, February 1, 2021 Evotec today announced that Dr Cord Dohrmann has been appointed to the German Council of Science and Humanities (German: “Wissenschaftsrat”) for a term of three years. He is appointed by the Federal President Frank-Walter Steinmeier on the joint recommendation of the German Federal Government and the governments of the German states. Evotec Starts Clinical Development of Chikungunya Antibody together with NIAID and Leading Academic Research Organisation Hamburg, Germany, January 28, 2021 Evotec SE today announced that EVT894, a monoclonal antibody to treat and potentially prevent chikungunya virus infections, has entered clinical development. Just – Evotec Biologics Expands Contract with the Department of Defense for Manufacturing of Monoclonal Antibodies Hamburg, Germany, January 27, 2021 Evotec SE today announced that the U.S. Department of Defense (“DOD”) awarded its Seattle, Washington-based subsidiary, Just – Evotec Biologics, Inc., an agreement worth $28.6 million for the production of monoclonal antibodies (“mAbs”) for use in the development of a treatment and/or prophylaxis for COVID-19. Evotec to attend upcoming investor conferences Hamburg, Germany, January 7, 2021 Evotec SE announced today that its management will be presenting at and attending the following upcoming conferences in the first quarter of 2021: Evotec achieves milestone in its neurodegeneration collaboration with Bristol Myers Squibb Hamburg, Germany, January 5, 2021 Evotec SE announced today that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company (NYSE:BMY) within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio. 2020 Evotec partners with Alloy Therapeutics to expand its antibody discovery platform Hamburg, Germany, December 21, 2020 Evotec SE and Alloy Therapeutics, a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all, today announced that the companies have entered into a technology partnership to expand Evotec’s antibody discovery platform. Autobahn Labs and UCSF Announce Strategic Drug Discovery Collaboration Palo Alto and San Francisco, CA, USA, December 21, 2020 Autobahn Labs, a virtual incubator partnering with top academic and research institutions to catalyze early-stage drug discovery and development, today announced a strategic collaboration with the University of California San Francisco (UCSF). The organizations will partner to identify promising early science with significant therapeutic potential, forming jointly owned ventures to accelerate the translation of scientific ideas to novel therapeutics. Evotec achieves key milestones in its collaboration with Bristol Myers Squibb on targeted protein degradation Hamburg, Germany, December 17, 2020 Evotec SE today announced that the Company has achieved key milestones in its partnership with Bristol Myers Squibb in the field of targeted protein degradation with the first two targets transitioning into drug discovery after completing a comprehensive target validation process. Evotec and Sartorius partner with start-up Curexsys on iPSC-based exosome approach Hamburg, Germany, December 9, 2020 Evotec SE and the life science company Sartorius announced today that they have entered into a partnership with the recently established Curexsys GmbH, a Goettingen, Germany-based technology leader specialising in the emerging field of therapeutic exosomes. Evotec publishes DDup 10 – Evotec’s transforming transcriptomics toxicology platform Hamburg, Germany, December 2, 2020 The 10th edition is dedicated to our newly developed next generation transcriptomics toxicology platform, a truly translational project across different groups at Evotec. Evotec and Rappta Therapeutics enter discovery and development partnership focused on oncology target Hamburg, Germany, November 24, 2020 Evotec SE today announced a new multi-year drug development partnership with Rappta Therapeutics, a Finland-based biopharmaceutical company, focused on an innovative oncology target. Evotec presents growth drivers of "Autobahn to Cures" at Capital Markets Day Hamburg, Germany, November 19, 2020 Recorded webcast now available Evotec and STORM Therapeutics leverage INDiGO platform to progress oncology project towards clinical studies Hamburg, Germany, November 17, 2020 Evotec SE announced today that, as part of its ongoing collaboration with STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, STORM has selected STC-15 as a first-in-class development candidate. STORM will now use INDiGO, Evotec’s unique integrated, accelerated IND-enabling platform, to progress STC-15 towards an IND application in 2021. Evotec SE reports results for the first nine months of 2020 and provides corporate update Hamburg, Germany, November 12, 2020 MULTIPLE NEW & EXTENDED DRUG DISCOVERY AND DEVELOPMENT ALLIANCES; VERY GOOD PROGRESS IN CO-OWNED PIPELINE; INCREASING MOMENTUM DESPITE DIFFICULT BUSINESS ENVIRONMENT; GUIDANCE FOR FULL-YEAR 2020 CONFIRMED; CAPACITY EXPANSION ON TRACK FOR SWIFT START TO 2021 Evotec expands Oxfordshire site into a fully-integrated R&D centre named "Dorothy Crowfoot Hodgkin Campus" Hamburg, Germany, November 12, 2020 Evotec SE today announced the expansion of the Company’s existing campus based at Milton Park in Abingdon, Oxfordshire, UK, into a major, fully-integrated, co-located discovery and development centre to be named Dorothy Crowfoot Hodgkin Campus. Adding a new building, which will house up to 100 biologists by the end of the year, will bring together all the key functions for cutting-edge and high-performance small molecule discovery and up to commercial development. Evotec SE to announce results for the first nine months 2020 on 12 November 2020 Hamburg, Germany, November 5, 2020 Evotec SE will announce its financial results for the first nine months of 2020 on Thursday, 12 November 2020. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English Evotec to attend upcoming investor conferences Hamburg, Germany, November 4, 2020 Evotec SE announced today that its management will be presenting at and attending upcoming conferences until the end of 2020. Eternygen Announces the First Closing of its Series A2 Funding Round Berlin, Germany, October 26, 2020 Eternygen today announced the first closing of its Series A2 funding round led by new anchor investor Evotec SE and additional funding from venture capital firms Epidarex Capital, IBB Ventures and a number of family offices. The new investment amounting to € 5 m will be used to drive Eternygen’s development of novel treatments for non-alcoholic steatohepatitis ("NASH") to the next milestone, i.e. the selection of a preclinical development candidate, the initiation of IND enabling studies as well as growing clinical capabilities within the team. Just - Evotec Biologics receives grant to enable an antibody product for the prevention of COVID-19 Hamburg, Germany, October 19, 2020 Evotec SE today announced that its Seattle-based subsidiary, Just – Evotec Biologics, Inc., received a grant from the Bill & Melinda Gates Foundation (Seattle, WA) as part of the COVID-19 Therapeutics Accelerator to enable the development and production of monoclonal antibody (“mAb”) candidates for the prevention of severe COVID-19 in vulnerable populations in low and middle income countries. Topas Therapeutics Raises € 22 m (~US$ 26 m) in Series B Financing and appoints Klaus Martin, Ph.D. as Chief Executive Officer Hamburg, Germany, October 19, 2020 Topas Therapeutics GmbH, a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, today announced the successful closing of a € 22 m (~US$ 26 m) Series B financing round. MUBADALA INVESTMENT COMPANY AND NOVO HOLDINGS A/S INVEST € 250 M IN EVOTEC SE Hamburg, Germany, October 13, 2020 Evotec SE today announced that it resolved a capital increase from its authorised capital without pre-emptive rights against cash. Evotec will issue a total of 11,478,315 new shares to Mubadala Investment Company and Novo Holdings A/S, increasing Evotec’s cash reserves by € 250 million in total. Evotec achieves milestone in neurodegeneration collaboration with Bristol Myers Squibb Hamburg, Germany, October 8, 2020 Evotec SE announced today that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company following the decision to expand the portfolio by another drug discovery project. Evotec and BIOASTER partner to build a technology and innovation hub in Lyon Hamburg, Germany, September 14, 2020 Evotec SE and the French-based BIOASTER Technological Research Institute today announced that they have entered into a partnership to advance research for infectious diseases. BIOASTER is a technology and innovation hub located in Lyon, France that has created a new model to address the latest challenges in the microbiology field, including antimicrobial resistance and vaccine safety and efficacy. Evotec expands at Milton Park to become one of its largest occupiers Abingdon, UK, September 9, 2020 Evotec, a leading drug discovery alliance and development partnership company, has taken additional office and laboratory space at Milton Park, one of the leading science and technology communities in Europe, to bring its total occupation to 192,745 sq ft making it one of the largest occupiers on the Park. Evotec expands its proprietary patient database into liver disease with unique access to QUOD biobank Hamburg, Germany, September 2, 2020 Evotec SE today announced a partnership agreement with the University of Oxford regarding access to biospecimens from the biobank Quality in Organ Donation (“QUOD”), an initiative of The Nuffield Department of Surgical Sciences (“NDS”) at the University of Oxford in close collaboration with the National Health Service Blood and Transplant (“NHSBT”) organisation in the UK. Evotec and CENTOGENE expand collaboration into Gaucher disease Hamburg and Rostock, Germany, August 20, 2020 Evotec SE and CENTOGENE N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that the companies have expanded their existing drug discovery partnership related to the protein target glucocerebrosidase (“GBA”) with a focus on Gaucher disease, a genetic and relatively common lysosomal storage disorder. The parties intend to develop a treatment option for the majority of patients whereas currently available treatments are individualised for each patient depending on the type of Gaucher disease, focusing on symptomatic relief. Evotec and Novo Nordisk form strategic alliance to develop novel therapies for kidney diseases Hamburg, Germany, August 18, 2020 Evotec SE and Novo Nordisk today announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease. Evotec and Novo Nordisk will jointly identify and develop novel targets based on comprehensive medical and molecular data sets of thousands of chronic kidney disease patients. The collaboration intends to pursue the most relevant human disease biology in a therapeutic modality-agnostic approach to develop first-in-class therapeutics for patients suffering from CKD. Evotec SE reports first half-year 2020 results and corporate updates Hamburg, Germany, August 12, 2020 Evotec SE today announced its financial results for the first half-year of 2020: Significant Group revenue growth of 12% to € 231.0 m (H1 2019: € 207.1 m); Revenue growth in both business segments: EVT Execute revenues up 16% to € 228.2 m (H1 2019: € 196.8 m); EVT Innovate revenues up 8% to € 44.6 m (H1 2019: € 41.2 m); Adjusted Group EBITDA amounting to € 47.3 m (H1 2019: € 58.2 m) Evotec receives CARB-X funding for Resolute's antibiotic project Hamburg, Germany, August 11, 2020 Evotec SE announced today that the Company has entered into a new partnership with the Biotech company Resolute Therapeutics (“Resolute”) to combat infectious diseases and antimicrobial resistance. The partnership aims to develop a broad-spectrum antibiotic with a new mode of action compared to antibiotics currently on the market and will receive substantial funding from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership led by Boston University and dedicated to funding and supporting the development of therapeutics, vaccines and rapid diagnostics to address the most serious drug-resistant bacteria. Evotec and Secarna Pharmaceuticals form strategic partnership in the field of antisense therapy Hamburg and Marburg, Germany, August 5, 2020 Evotec SE and the leading independent European antisense drug discovery company, Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), today announced a strategic partnership in the field of antisense oligonucleotide (“ASO”)-based therapeutics. Antisense therapy is an innovative, clinically and commercially validated, highly-targeted pharmacological approach which interferes with gene expression in the cells of interest to specifically inhibit the production of proteins which promote development and progression of diseases. Evotec SE to report first half-year 2020 results on 12 August 2020 Hamburg, Germany, August 5, 2020 Evotec SE will report its financial results for the first half-year of 2020 on Wednesday, 12 August 2020. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for the fiscal year 2020. The conference call will be held in English. Just - Evotec Biologics to produce monoclonal antibody products against COVID-19 for the Department of Defense Hamburg, Germany, July 22, 2020 Evotec SE today announced that the U.S. Department of Defense (“DOD”) awarded its Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 18.2 m to develop and manufacture monoclonal antibodies (“mAbs”) for treatment and/or prevention of COVID-19. The goal of this programme is to rapidly and efficiently deliver the mAbs to the DOD. Evotec enters partnership with QUANTRO Therapeutics Hamburg, Germany, July 21, 2020 Evotec SE announced today that the Company has entered into a comprehensive partnership with the recently established QUANTRO Therapeutics GmbH (“QUANTRO”), a research-based biotech company based in Vienna, Austria, that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programmes in cancer and other diseases. Evotec initiates “Campus Curie” in Toulouse Hamburg, Germany, July 8, 2020 Evotec SE today announced that Evotec has added significant opportunity for further, long-term growth of its Toulouse-based operations by taking over “Biopark by Sanofi”. Evotec publishes DDup 9 – Evotec’s iPSC-based TargetRD programme Hamburg, Germany, July 6, 2020 The 9th edition of DDup is dedicated to our unique and innovative iPSC-based drug discovery programme TargetRD (Retinal Disease), which we have developed in collaboration with our colleagues from the Centre for Regenerative Therapies TU Dresden. Evotec, Samsara BioCapital, and KCK launch Autobahn Labs Hamburg, Germany, June 24, 2020 Evotec SE, Samsara BioCapital, a leading life sciences investment firm, and KCK Ltd., a family investment fund, today announced the launch of Autobahn Labs, a novel virtual incubator partnering with top academic and research institutions to catalyse early-stage drug discovery and development. Evotec SE virtual Annual General Meeting 2020 approves all proposed agenda items Hamburg, Germany, June 16, 2020 Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s virtual Annual General Meeting 2020 with the required majority. Due to the COVID-19 pandemic, this year’s Annual General Meeting was held as a purely virtual event. Just - Evotec Biologics partners with ABL on development of broadly neutralising antibody against HIV Hamburg, Germany, June 8, 2020 Evotec SE today announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has entered into an agreement with Advanced BioScience Laboratories, Inc. (“ABL”), a global contract development and manufacturing organisation (“CDMO”) to the U.S. Government and biopharmaceutical industry. Evotec: Cyprotex awarded new 5 year agreement with the US Environmental Protection Agency ("EPA") Hamburg, Germany, June 3, 2020 Evotec SE today announced that its wholly owned subsidiary Cyprotex US, LLC has been awarded a new 5 year contract with the US Environmental Protection Agency (“EPA”). The project forms part of the EPA’s Computational Toxicology and Exposure Research efforts (“CompTox”) whose goal is to provide solutions-driven research to rapidly evaluate the potential human health and environmental risks due to exposures to environmental chemicals. Evotec participates in Exscientia's financing round Hamburg, Germany, May 26, 2020 Evotec SE today announced that the Company has participated in the Series C funding round of Exscientia, the world-leading Artificial Intelligence (“AI”)-driven drug discovery company. The funding round led by new investor Novo Holdings raised $ 60 m with the existing investors’ consortium consisting of Evotec, Bristol Myers Squibb, and GT Healthcare Capital also participating in the round. Evotec SE reports first quarter 2020 results and provides corporate update Hamburg, Germany, May 14, 2020 Evotec SE today announced the financial results and corporate updates for the first quarter 2020. 15% increase in group revenues from contracts with customers to € 119.4 m; Strong revenue growth in both segments: EVT Execute revenues up 18% to € 118.2 m (Q1 2019: € 100.3 m), EVT Innovate revenues up 24% to € 23.3 m (Q1 2019: € 18.8 m); Stable adjusted Group EBITDA of € 30.0 m (Q1 2019: € 30.0 m); adjusted EBITDA of € 35.4 m for EVT Execute (Q1 2019: € 32.2 m); No material impact by COVID-19 pandemic on financial development so far Consortium backs successful LAB150 project Toronto, Canada, May 12, 2020 Evotec SE and its collaborators Toronto Innovation Acceleration Partners (“TIAP”) and AmorChem Therapeutics today announced a $ 1.75 m investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide. Evotec SE to report first quarter 2020 results on 14 May 2020 Hamburg, Germany, May 7, 2020 Evotec SE will report its financial results for the first quarter of 2020 on Thursday, 14 May 2020. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for the fiscal year 2020. Just - Evotec Biologics to collaborate with Ology Bioservices on antibodies against Coronavirus Hamburg, Germany, April 30, 2020 Evotec SE today announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has entered into a partnership with Ology Bioservices, Inc. (“Ology Bio”) for the evaluation and analytical characterisation of antibodies against SARS-CoV-2. Evotec regains global rights to beta cell replacement therapy Hamburg, Germany, April 22, 2020 Evotec SE announced today that it will regain global development and commercialisation rights to the iPSC-based programme for the treatment of diabetes developed under collaboration agreement with Sanofi. Evotec enters nanomedicine through strategic partnership with leon-nanodrugs Hamburg, Germany, April 16, 2020 Evotec SE today announced a strategic partnership and equity investment with leon-nanodrugs GmbH (“leon”). Based in Munich, Germany, leon is the leading enabler of nanotechnology for the pharmaceutical industry. Under the terms of the agreement, Evotec and leon will cooperate on selected development programmes and maximise the effectiveness of clinical and commercial nanomedicines. Just – Evotec Biologics develops AI-driven humanoid antibody library (“HAL”) Seattle, USA, April 15, 2020 Just – Evotec Biologics announced today that the Company has compiled a library of a new class of humanoid antibodies using a novel, AI-derived approach. Antibodies are proteins produced and secreted by B-cells. As they bind to foreign substances that invade the body, such as pathogens and a plethora of other targets, they represent an important class of biologics-based therapeutics. Evotec expands into gene therapy Hamburg, Germany, April 6, 2020 Evotec SE today announced that the Company has established a dedicated site for research and development of gene therapy-based projects: Evotec Gene Therapy (“Evotec GT”) which will start operations with a strong team of gene therapy experts at an R&D site in Orth/Donau, Austria. Evotec and Takeda enter into multi-year gene therapy research alliance Hamburg, Germany, April 6, 2020 Evotec SE today announced that Evotec GT, with operations in Austria, has established a long-term research alliance with Takeda to support Takeda’s growing number of research stage gene therapy discovery programmes. Evotec GT is an integral part of Evotec’s integrated fully modality-agnostic drug discovery platform that combines all activities involved with the discovery, development, and manufacturing of therapeutics along the value chain. Evotec expands its iPSC-based cell therapy platform EVOcells through licensing agreement with panCELLa Hamburg, Germany, and Toronto, Canada, April 2, 2020 Evotec SE and the innovative biotechnology company panCELLa Inc. announced today that the companies have entered into a licensing and investment agreement. Under the terms of the agreement, Evotec will receive a non-exclusive licence to access panCELLa’s proprietary iPS cell lines “iACT Stealth Cells™”, which are genetically modified to prevent immune rejection of derived cell therapy products (“cloaking”). Evotec and Ildong to collaborate with development projects on INDiGO platform Hamburg, Germany, March 31, 2020 Evotec SE announced today that the Company has entered into a strategic collaboration with Ildong Pharmaceutical Co., Ltd. (“Ildong”), a leading pharmaceutical company in South Korea, to accelerate the development of several of Ildong’s proprietary projects through access to Evotec’s INDiGO platform. Evotec SE fiscal year 2019 results: : Excellent 2019 performance; very good outlook for continued growth 2020 Hamburg, Germany, March 26, 2020 Evotec SE today reported financial results and corporate updates for the fiscal year ended 31 December 2019. Group revenues up 19% to € 446.4 m, adjusted Group EBITDA up 29% to € 123.1 m, unpartnered R&D expenses of € 37.5 m, liquidity position more than doubled to € 320.0 m. Evotec partner Forge enters into collaboration with Roche to develop novel antibiotic San Diego, USA, March 25, 2020 Evotec’s partner Forge Therapeutics, Inc. (“Forge”) today announced a research collaboration and option agreement with Hoffmann-La Roche Ltd. (“Roche”) to license one of its novel antibiotics for the treatment of hospital-based lung infections. The targeted infections includes those cited on the CDC’s most urgent threats list, which commonly occur in people with weakened immune systems and chronic lung diseases. Evotec SE to report fiscal year 2019 results on 26 March 2020 Hamburg, Germany, March 19, 2020 Evotec SE will report its financial results for 2019 on Thursday, 26 March 2020. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2020. First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis Hamburg, Germany, February 27, 2020 Today a consortium of philanthropic, non-profit and private sector organizations launched a collaboration that aims to accelerate the development of novel “pan-TB” drug regimens for the treatment of tuberculosis (TB) that are ready for phase 3 development. The regimens will be designed to have little to no drug resistance and an acceptable safety profile, and be better-tolerated, shorter in duration and simpler to use than existing options. Such regimens are intended to be a central component of efforts to address the current complexities and challenges of TB treatment. Infographic: How to find effective endometriosis treatments by Larissa Warneck, Labiotech, February 5, 2020 The exact number of women suffering from endometriosis is unknown. However, it is estimated that 10% of women worldwide are affected. Endometriosis is a debilitating disease in which the endometrial cells that usually line the uterus are found in other regions of the body. Evotec and Bayer advance further programme into Phase I clinical development Hamburg, Germany, January 30, 2020 Evotec SE announced today that its partner Bayer AG has decided to advance a further programme from the endometriosis multi-target alliance into clinical Phase I development. Evotec and Indivumed announce second joint drug discovery programme Hamburg, Germany, January 23, 2020 Evotec SE and Indivumed today announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (“NSCLC”). Just – Evotec Biologics announces product development and manufacturing agreement with OncoResponse Hamburg, Germany, January 16, 2020 Evotec SE today announced that its wholly-owned Seattle-based subsidiary company Just – Evotec Biologics, Inc. has established a collaborative relationship with OncoResponse, Inc., a biotech company developing human antibodies as product candidates for multiple high value targets associated with immunosuppressive myeloid biology. Just – Evotec Biologics initiates construction of first J.POD® facility in North America Hamburg, Germany, January 14, 2020 Evotec SE today announced that the wholly-owned Seattle-based company Just – Evotec Biologics initiated the construction of a late-stage clinical and commercial manufacturing facility for biologics in Redmond, Washington. Just – Evotec Biologics enters into multi-year collaboration with MSD around facility of the future Hamburg, Germany, January 14, 2020 Evotec SE today announced that its wholly-owned Seattle-based subsidiary company Just – Evotec Biologics, Inc. has expanded its collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, regarding the development of innovative technologies for the production of biologics of the highest quality. Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome Hamburg and Berlin, Germany, January 9, 2020 Evotec SE and Bayer AG today announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”). Evotec and Bristol-Myers Squibb expand iPSC collaboration Hamburg, Germany, January 7, 2020 Evotec SE announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company following the decision to expand the collaboration to include additional cell lines. Evotec to attend upcoming investor conferences Hamburg, Germany, January 2, 2020 Evotec SE announced today that its management will be presenting at and attending investor conferences in January and February 2020. 2019 Evotec achieves third milestone in cell therapy diabetes alliance with Sanofi Hamburg, Germany, December 19, 2019 Evotec SE today announced successful achievement of a third milestone in their diabetes research alliance with Sanofi, resulting in a payment of € 3 m to Evotec. This milestone was triggered after Evotec met pre-agreed critical criteria within the beta cell replacement therapy programme. Evotec expands service agreement with Sanofi to create a centralised global sample management hub in Toulouse Hamburg, Germany, December 18, 2019 Evotec SE today announced plans to extend its sample management activities through an expansion of its service agreement with Sanofi. Under the terms of the new agreement, Sanofi will transfer its liquid compounds to Evotec in Toulouse over the next 2 years. Evotec spin-off Topas Therapeutics announces start of Phase 1 trial with TPM203 in pemphigus vulgaris Hamburg, Germany, December 18, 2019 Evotec spin-off Topas Therapeutics GmbH (“Topas”), a Hamburg, Germany-based private platform company leveraging the natural tolerance induction capabilities of the liver, today announced that the first patient has been enrolled in a first-in-human Phase 1 trial evaluating TPM203 in patients with pemphigus vulgaris ("PV"), an orphan autoimmune disease. Toronto Innovation Acceleration Partners ("TIAP") adds novel KRAS oncology project to its LAB150 portfolio Toronto, Canada, December 12, 2019 Toronto Innovation Acceleration Partners ("TIAP") announced today the launch of a new project developed under the BRIDGE LAB150, a partnership between Evotec SE and TIAP. The project will be focusing on breakthroughs in novel cellular drug screening systems in oncology-focused scientific KRAS research by Professor Igor Stagljar at the University of Toronto, a TIAP Member, and aims to develop therapeutics targeting the protein-protein interactions of KRAS and its downstream interacting partners. Working together in the fight against tuberculosis and malaria Braunschweig and Saarbrücken, Germany, December 9, 2019 New medicines for treating tuberculosis, malaria and other infectious diseases are still urgently needed, particularly in developing countries. The spread of antibiotic-resistant germs also results in a critical shortage of effective medications for treating and containing infectious diseases. Although this is a global problem, developing and emerging countries are particularly affected. Evotec expands strategic partnership with Celmatix in women's health Hamburg, Germany, December 3, 2019 Evotec SE today announced an expansion of the Company’s strategic partnership with Celmatix Inc., the leading precision health company advancing the fields of reproductive medicine and fertility at the intersection of big data and genomics. Addressing Discovery and Development Challenges in Biologics by Larissa Warneck, Labiotech, November 27, 2019 The biologics industry is growing at an incredible rate. While its global market value was estimated at $ 236 bn in 2017, it is expected to rise to $ 310 bn by 2023. As key market players enter the field, competition is increasing. Immunitas Therapeutics Launches with $39 Million Series A to Advance Lead Programs to Human Efficacy Studies Based on a Unique Human Immunology-Focused Drug Development Platform Boston, MA, USA, November 21, 2019 Immunitas Therapeutics, a single cell genomics-based drug discovery company founded by Longwood Fund, today announced a $39 million Series A financing led by Leaps by Bayer and Novartis Venture Fund and joined by additional investors including Evotec, M Ventures, Alexandria Venture Investments, and other institutional investors. Evotec to attend upcoming investor conferences Hamburg, Germany, November 14, 2019 Evotec SE announced today that its management will be presenting at and attending upcoming conferences in November and December 2019. Evotec SE reports first nine-month 2019 results and corporate updates Hamburg, Germany, November 12, 2019 Evotec SE today reported financial results and corporate updates for the first nine months ended 30 September 2019. Merck licenses CRISPR gene-editing technology to Evotec Darmstadt, Germany, November 12, 2019 Merck today announced that it has signed a license agreement providing Evotec SE access to Merck’s foundational CRISPR intellectual property. Evotec and Vifor Pharma form joint venture for early development in nephrology Hamburg, Germany; St. Gallen, Switzerland, November 6, 2019 Evotec SE and Vifor Pharma today announced the launch of a 50:50 joint venture focused on the discovery and development of novel nephrology therapeutics. Vifor Pharma will be benefiting from access to an external R&D capability for the development of its own nephrology pipeline, while Evotec will gain access to a commercial partner through outlicensing all nephrology assets developed through the joint venture to the Vifor Pharma Group. Evotec SE to announce results for the first nine months 2019 on 12 November 2019 Hamburg, November 5, 2019 Evotec SE will announce its financial results for the first nine months of 2019 on Tuesday, 12 November 2019. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. Evotec, Integra Holdings and Yissum establish LAB555 to fast track early-stage drug development Hamburg, Germany, October 23, 2019 Evotec SE today announced the inauguration of LAB555, an academic BRIDGE partnership with Integra Holdings and Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem. Just – Evotec Biologics & Biocon Biologics sign licensing deal for a biosimilar asset Hamburg, Germany, Seattle, USA, and Bengaluru, India, October 10, 2019 Evotec SE and Biocon Limited today announced that Biocon Biologics, a wholly owned subsidiary of Biocon Ltd, and Just – Evotec Biologics, wholly owned by Evotec, have entered into a strategic licensing agreement for an early-stage, pre-clinical biosimilar asset. Evotec and Celmatix enter into strategic collaboration Hamburg, Germany, and New York, USA, October 9, 2019 Evotec SE and Celmatix Inc., a precision medicine company with a proprietary multi-omics platform, today announced a partnership to develop pre-clinical programmes in prevalent but underserved conditions affecting women’s reproductive health, including polycystic ovary syndrome (“PCOS”), endometriosis, and infertility. Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian Hamburg, Germany, October 4, 2019 Evotec SE today announced that the Company has reached a milestone in a drug discovery and development partnership with the biopharmaceutical company Aeovian Pharmaceuticals, Inc. (“Aeovian"). Evotec and Indivumed achieve milestone in joint strategic drug discovery collaboration Hamburg, Germany, September 30, 2019 Evotec SE and Indivumed GmbH announced today that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer. Evotec and Takeda enter collaboration agreement to discover clinical candidates across multiple therapeutic areas Hamburg, Germany, September 24, 2019 Evotec SE today announced a strategic, multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). Under the collaboration, the parties aim to establish at least five drug discovery programmes with the goal of Evotec delivering clinical candidates for Takeda to pursue into clinical development. Evotec to attend upcoming investor conferences Hamburg, Germany, September 6, 2019 Evotec SE announced today that its management will be presenting at and attending investor conferences in September and October. Evotec SE reports first half-year 2019 results and corporate updates Hamburg, Germany, August 14, 2019 Evotec SE today reported financial results and corporate updates for the first half of 2019. Group revenues up 16% to € 207.1 m (H1 2018: € 178.9 m). Adjusted Group EBITDA up 51% to € 58.2 m (H1 2018: € 38.6 m). Unpartnered R&D expenses of € 18.7 m (H1 2018: € 10.0 m). Strong liquidity position of € 341.8 m (31 December 2018: € 149.4 m) following issue of € 250 m promissory note (Schuldschein) and final repayment of € 140 m acquisition bridge facility. Evotec SE to report first-half year 2019 results on 14 August 2019 Hamburg, Germany, August 7, 2019 Evotec SE will report its financial results for the first half of 2019 on Wednesday, 14 August 2019. New IMI project “GNA NOW” kicks off its battle against antimicrobial resistance Hamburg, Germany, August 1, 2019 Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel antibacterial agents today: Gram-Negative Antibacterials NOW (“GNA NOW”). Evotec SE: P2X3 antagonist demonstrates efficacy against refractory chronic cough in Phase II (POC) Hamburg, Germany, July 25, 2019 Evotec SE today announced that the Company has been notified by its partner Bayer about the successful outcome of a combined Phase I/IIa study with the P2X3 antagonist BAY1817080, originating from the Evotec/Bayer multi-target alliance. Evotec expands its iPSC discovery platform Hamburg, Germany, July 15, 2019 Evotec SE today announced that the Company has acquired assets from the stem cell specialist Ncardia AG to advance Evotec’s iPSC platform, one of the leading iPSC-based discovery platforms in the industry. Evotec and venture capital consortium form "Breakpoint Therapeutics GmbH" Hamburg, Germany, July 8, 2019 Evotec SE today announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers. Breakpoint Therapeutics’ mission is to develop first and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of therapy-resistant cancers. Evotec completes acquisition of Just Biotherapeutics Hamburg, Germany, July 3, 2019 Evotec SE today announced that the strategic transaction to acquire Just Biotherapeutics (“Just.Bio”), signed on 20 May 2019, has been completed. The acquisition accelerates Evotec’s long-term strategy to be the industry partner of choice for external end-to-end innovation, strengthening Evotec’s multimodality approach to R&D. Evotec acquired Just.Bio to integrate their cutting-edge machine-learning technologies and agile, flexible methods for the design, development, and manufacturing of biologics into Evotec’s drug discovery offerings. Just Biotherapeutics and Teva enter an agreement for the design and development of a high productivity (HP) biomanufacturing process Seattle, USA, June 28, 2019 Just Biotherapeutics, Inc., an integrated design company focused on technologies for accelerating the development and manufacture of biotherapeutics, announced today that they have entered into an agreement with Teva for the design and development of a high productivity (HP) biomanufacturing process. Evotec SE places first Schuldschein (Promissory note) worth € 250 m Hamburg, Germany, June 26, 2019 Evotec SE announced today that the Company successfully issued a Schuldschein (promissory note) of € 250 m on the capital market. The Schuldschein was placed with a fixed and variable interest rate of on average below 1.5 percent over 3, 5, 7, and 10 years maturity. Following high demand from debt investors, which led to a significant oversubscription of the order book and attractive credit spreads, the initial target volume of € 100 m could be successfully increased to € 250 m. Evotec, Sensyne Health, the University of Oxford, OSI, and OUI create new bridge partnership “LAB10x” in digital health Hamburg, Germany and Oxford, UK, June 24, 2019 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it has entered into a new strategic partnership with the British clinical AI technology company Sensyne Health plc (LSE:SENS) (“Sensyne”), the University of Oxford, Oxford University Innovation Ltd (“OUI”, the university's research commercialisation company), and Oxford Sciences Innovation (“OSI”, the world's largest IP investment company dedicated to a single university) to fund a new BRIDGE called LAB10x. Resolutions of the Annual General Meeting 2019 of Evotec SE Hamburg, Germany, June 19, 2019 Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2019 with very strong supporting majorities. New LAB150 project identified Toronto, Canada, June 11, 2019 MaRS Innovation has announced the launch of a fifth project to be developed under the BRIDGE LAB150, a partnership between Evotec SE and MaRS Innovation. The aim of the project is to develop a novel rapid-acting antidepressant with the potential to provide patient relief much faster than conventional treatments. Evotec receives $ 23.8 m grant to join the global fight against tuberculosis Hamburg, Germany, June 10, 2019 Evotec SE today announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis (“TB”), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide. The current standard treatment regimen for TB consists of a minimum of 6 months of treatment with 4 drugs administered under direct observation, but treatment is much longer when TB is drug resistant. Evotec and Celgene further expand iPSC collaboration including new cell type Hamburg, Germany, June 5, 2019 Evotec SE announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Evotec publishes DDup 8: Evotec’s unique iPSC-based drug discovery platform Hamburg, Germany, May 29, 2019 The 8th edition of DDup is dedicated to our highly innovative iPSC platform, which we started developing more than six years ago with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach highest industrial standards. Today, it represents one of the largest and most sophisticated iPSC platforms in the industry. Evotec jump-starts biologics with acquisition of Just Biotherapeutics Hamburg, Germany, May 20, 2019 Evotec SE announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”), for up to $ 90 m including potential performance-based earn-out components expected within the next three years. Evotec to attend upcoming investor conferences Hamburg, Germany, May 15, 2019 Evotec SE announced today that its management will be presenting at and attending the following upcoming conferences: Berenberg Conference USA 2019, Tarrytown, NY, USA 2019 RBC Capital Markets Global Healthcare Conference, New York, NY, USA dbAccess Berlin Conference 2019, Berlin, Germany Jefferies 2019 Healthcare Conference, New York, NY, USA Evotec SE reports first quarter 2019 results and provides corporate update Hamburg, Germany, May 14, 2019 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today reported financial results and corporate updates for the first quarter of 2019. Evotec SE to report first quarter 2019 results on 14 May 2019 Hamburg, Germany, May 7, 2019 Evotec SE will report its financial results for the first quarter of 2019 on Tuesday, 14 May 2019. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2019. The conference call will be held in English. Evotec completes repayment of € 140 m acquisition loan Hamburg, Germany, April 18, 2019 Evotec SE today announced that it has completed the repayment of the € 140 m debt bridge facility Evotec drew down in context of the acquisition of Aptuit in 2017. Effective August 2017, Evotec acquired Aptuit, a partner research organisation for integrated outsourced drug discovery and development, for € 253.2 m in cash. This acquisition was financed through existing cash reserves and a new € 140 m senior debt bridge facility. Evotec and Indivumed announce strategic drug discovery collaboration on precision medicine for colorectal cancer Hamburg, Germany, April 11, 2019 Evotec SE and Indivumed GmbH announced today that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”). The collaboration, which runs for an initial term of two years, will combine Evotec’s proprietary bioinformatics analysis platform “PanHunter” as well as its small molecule and antibody discovery platforms with the CRC cohort of Indivumed’s true multi-omics cancer database “IndivuType”. The goal of this precision medicine collaboration is to deliver highly effective and durable treatments with clear strategies for CRC patient stratification. Evotec AG completes conversion into Evotec SE Hamburg, Germany, April 1, 2019 Evotec SE announced today that it has completed its conversion into a company under European law (Societas Europaea, “SE”) with its registration in the commercial register of the District Court of Hamburg. It will operate under the registered name Evotec SE with the commercial register number HRB 156381 effective immediately and its headquarters will remain in Hamburg. The new legal form has no impact on the Company’s day-to-day operations. Evotec AG Fiscal Year 2018 results: Accelerated growth and strong long-term outlook Hamburg, Germany, March 28, 2019 Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2018. Evotec and The Mark Foundation for Cancer Research announce strategic collaboration in immuno-oncology Hamburg, Germany, March 26, 2019 Evotec AG and The Mark Foundation for Cancer Research today announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics in oncology. The collaboration, for an initial period of two years, is based on Evotec’s new proprietary drug discovery platform TargetAlloMod, which is focused on disrupting cell signalling via a novel mechanism of action. This approach is expected to deliver highly potent and more durable treatments for both clinically validated and novel immuno-oncology targets. Celgene and Evotec's partner Exscientia enter 3-year AI drug discovery collaboration focused on accelerating drug discovery in oncology and autoimmunity Oxford, UK, March 21, 2019 Evotec's partner Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered a three-year AI drug discovery partnership with leading biopharma company Celgene, including an initial $ 25 million upfront payment and eligibility to receive substantial milestones based on the clinical, regulatory and commercial success of the program. Evotec AG to report fiscal year 2018 results on 28 March 2019 Hamburg, Germany, March 21, 2019 Evotec AG will report its financial results for 2018 on Thursday, 28 March 2019. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2019. The conference call will be held in English. Evotec and GARDP announce new partnership to discover novel antibiotics Hamburg, Germany, and Geneva, Switzerland, March 19, 2019 Evotec AG and The Global Antibiotic Research and Development Partnership (“GARDP”) are today announcing the formation of a new strategic public-private partnership to tackle the growing threat of antimicrobial resistance (“AMR”). By joining forces, Evotec and GARDP will leverage their capabilities and networks to address drug-resistant bacterial infections. This includes bringing together GARDP’s clinical expertise and sustainable access commitment with Evotec’s leading drug discovery platform, expertise in medicinal chemistry and pharmacology, as well as its world-leading collection of bacterial pathogens. Evotec to attend upcoming investor conferences Hamburg, Germany, March 7, 2019 Evotec AG announced today that its management will be presenting at and attending the following upcoming conferences: BioCapital Europe, Bankhaus Lampe Deutschlandkonferenz, H.C. Wainwright Global Life Sciences Conference, Kempen & Co Life Sciences Conference. Evotec receives milestone payment for start of second Phase II trial in its multi-target alliance with Bayer Hamburg, Germany, February 28, 2019 Evotec AG announced today that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough. As a result of the trial initiation, Evotec received a payment of € 3 m. In October 2012, Evotec and Bayer began their multi-target discovery alliance with the shared goal to discover three clinical candidates with a focus in the field of endometriosis. The successful and productive long-term alliance ended in 2018, generating six first-in-class pre-clinical candidates three of which have progressed into Phase I clinical trials. Two new LAB150 projects identified to create novel therapeutics for Cystic Fibrosis and Respiratory Syncytial Virus Toronto, Canada, February 27, 2019 MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both of which are Members of MaRS Innovation. The projects aim to develop novel therapeutics for the treatment of cystic fibrosis and of respiratory syncytial virus, respectively. Evotec and Helmholtz Centre joining platforms and forces for novel antibiotics Hamburg and Braunschweig, Germany, February 20, 2019 Evotec AG and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics that overcome drug-resistant bacterial pathogens. Research activities will initially be focused on the optimisation of cystobactamids, a family of natural antibacterial products with innovative chemical scaffolds that are active against the most dangerous Gram-negative pathogens on the WHO priority list. Evotec and Galapagos enter into collaboration in the field of fibrosis Hamburg, Germany, and Mechelen, Belgium, February 7, 2019 Evotec AG and Galapagos NV today announced a global collaboration focused on a novel target for fibrosis and other indications. The collaboration concerns a small molecule programme, currently in pre-clinical development for the treatment of fibrotic diseases of the liver and other organs. The target has been identified and validated using Evotec’s proprietary platforms for fibrotic diseases and NASH. Evotec utilised its in-house assay development and drug screening capabilities to identify small molecule modulators against the target, which remains undisclosed. Evotec mourns loss of Company co-founder Prof. Manfred Eigen Hamburg, Germany, February 7, 2019 Evotec AG mourns the loss of Nobel laureate and Company co-founder Prof. Manfred Eigen, who passed away on 06 February at the age of 91. Evotec receives milestone payment for start of Phase II clinical trial Hamburg, Germany, January 24, 2019 Evotec AG announced today that it has earned a $ 2 m milestone payment from Second Genome, Inc., a leading microbiome science-based discovery & development company, for the initiation of a Phase II clinical study of SGM 1019, a first-in-class oral therapeutic for the treatment of nonalcoholic steatohepatitis (NASH). The Phase II trial of SGM-1019 has been initiated following the completion of two successful Phase I trials. Cyprotex, an Evotec company, joins new European H2020 research project Hamburg, Germany, January 16, 2019 Evotec AG announced today that Cyprotex, an Evotec Company, will participate in the new European collaborative project SCREENED which aims to develop new 3D in-vitro tests to overcome limitations of existing tests. SCREENED aims to develop three-dimensional (3D) cell-based in vitro tests to better characterise the effects of endocrine disruptors on thyroid gland function. This method will overcome the limitations of existing tests, being more sensitive at low doses of exposure to chemicals, and enabling the prediction of their toxicity on human health in a sex-specific manner. Evotec reaches important scientific achievement within iPSC-based collaboration with Celgene Hamburg, Germany, January 8, 2019 Evotec AG announced today that its strategic alliance with Celgene Corporation (“Celgene”) has reached another important scientific achievement, resulting in Celgene designating a programme and triggering a payment of $ 14.0 m to Evotec. The payment was received by year-end 2018. This scientific achievement was the advancement of a programme into the lead optimisation stage developed from Evotec’s compound library using its induced pluripotent stem cell (“iPSC”)-based screening platform. This programme can be further optimised and progressed towards IND-ready status. Evotec invests in financing round of Exscientia Hamburg, Germany, January 7, 2019 Evotec AG announced today an additional investment of approximately $ 6 m towards Exscientia’s latest funding round (Series B). Exscientia, the world-leading Artificial Intelligence (AI)-driven drug discovery company, has raised $ 26 m in a Series B financing round. Celgene Corporation and GT Healthcare Capital Partners joined as new investors and Evotec, previously the only large external investor, fully participated in this round. Evotec to attend upcoming investor conferences Hamburg, Germany, January 4, 2019 Evotec AG announced today that its management will be presenting at and attending upcoming conferences: Evotec partner Forge receives second CARB-X award for up to $ 11.1 m Hamburg, Germany, January 4, 2019 Evotec AG today announced that its partner Forge Therapeutics has received a second award from CARB-X (Combating Antibiotic Resistant Bacteria) for developing a novel antibacterial therapeutic agent. 2018 Evotec to present at J.P. Morgan Healthcare Conference Hamburg, Germany, December 17, 2018 Evotec AG announced today that its management will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, USA. Evotec and LEO Pharma form drug discovery alliance targeting dermatological conditions Hamburg, Germany, and Ballerup, Denmark, December 4, 2018 Evotec AG today announced a new integrated drug discovery alliance with LEO Pharma, a global leader in medical dermatology. The collaboration goal is to generate new leads against innovative targets for a range of dermatological conditions and initially runs for two years. The collaboration leverages Evotec’s industry-leading hit identification platform including the extensive screening, structural biology and fragment-based drug design capabilities and expertise together with LEO Pharma’s 110-year track record of drug development and advancing science in dermatology. Evotec wins Scrip Award 2018 for "Business Development Team of the Year" Hamburg, Germany, November 29, 2018 Evotec AG announced today that the company won the Scrip Award 2018 for “Business Development Team of the Year”. This particular award recognises the achievements of Evotec’s Business Development Team over the last year, which has been characterised by many new alliances and partnerships between Evotec and partners from the pharmaceutical and biotech industry as well as academic institutes. LAB282: two years of drug discovery impact Hamburg, Germany, and Oxford, UK, November 22, 2018 LAB282, a unique funding-expertise hybrid model to accelerate Oxford therapeutics out of the lab and into the wider world, launched two years ago this month. Read about what it’s achieved so far, and what’s next for the partnership. Evotec and Immuneering to collaborate on artificial intelligence ("AI") driven ligand identification for rare hereditary metabolic diseases Hamburg, Germany, and Cambridge, USA, November 21, 2018 Evotec AG today announced that it has entered into a research collaboration with Immuneering Corporation (“Immuneering”), a worldwide leader in data-driven drug discovery, to discover novel small molecules for rare hereditary metabolic diseases. The research collaboration brings together Evotec’s leading induced pluripotent stem cell (“iPSC”) platform and broad drug discovery capabilities with Immuneering’s unique Artificial Intelligence-driven drug discovery platform to accelerate ligand identification for novel targets. Evotec AG reports first nine-month 2018 results and corporate updates Hamburg, Germany, November 13, 2018 Evotec AG today reported financial results and corporate updates for the first nine months of 2018: Strong operational and scientific performance; 57% increase in group revenues, 77% increase in adjusted group EBITDA; Strong outlook for 2018 confirmed and good underlying business indications for 2019; Webcast and conference call today at 02.00 pm CET Evotec wins award for "Sustained Excellence" at Deloitte's Technology Fast 50 Hamburg, Germany, November 9, 2018 Evotec AG announced today that the company has won one of the prestigious “Technology Fast 50” awards with which Deloitte honours the fastest-growing innovation drivers within the technology sector. At yesterday’s award ceremony, Evotec received the prize for “Sustained Excellence” which recognises the Company’s long-term growth, innovation capability, entrepreneurial spirit, as well as its sustainable corporate management. Evotec to attend upcoming investor conferences Hamburg, Germany, November 7, 2018 Evotec AG announced today that its management will be presenting and attending the following upcoming conferences: Jefferies London Healthcare Conference 2018, London, UK 15th Kempen London Conference, London, UK German Equity Forum 2018, Frankfurt am Main, Germany 16th Berenberg European Conference, Surrey, UK Evotec AG to report first nine-month 2018 results on 13 November 2018 Hamburg, Germany, November 6, 2018 Evotec AG will report its financial results for the first nine months of 2018 on Tuesday, 13 November 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. Evotec Partner Facio Therapies achieves first-ever in vivo proof of principle in FSHD Hamburg, Germany, October 31, 2018 Evotec partner Facio Therapies (“Facio”) announced today that oral treatment with one of Facio’s lead candidates results in significant reduction of the human muscle-toxic DUX4 protein in mice engrafted with human FSHD-affected muscle cells. Facio is the first in the FSHD field to achieve proof of principle in an animal model (“in vivo”). NCL foundation together with Evotec and Hamburg University explores new paths in juvenile NCL Hamburg, Germany, October 22, 2018 NCL foundation announces today that together with the biotechnology Company Evotec AG it supports a three-year PhD programme for research into juvenile neuronal ceroid lipofuscinosis (NCL). Under scientific supervision by Dr Guido Hermey (Hamburg University), the PhD programme will be based in the facilities and laboratories of Evotec AG. Evotec and Ferring form strategic research alliance in reproductive medicine and women`s health Hamburg, Germany, October 17, 2018 Evotec AG and Ferring Pharmaceuticals today announced a strategic research alliance to discover and develop new small molecule therapies to treat patients living with fertility and gynaecological conditions. Evotec and Celgene expand iPSC collaboration to include additional cell lines Hamburg, Germany, October 11, 2018 Evotec AG announced today that the Company will receive a $ 6 m payment from Celgene following Celgene’s decision to expand the collaboration to include additional cell lines. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’ symptoms and there is a huge unmet medical need for therapeutic modalities that slow down or reverse disease progression. Evotec signs agreement with Sanofi to advance early stage academic research into novel therapeutic candidates Hamburg, Germany, October 4, 2018 Evotec AG announced today that it has established an initiative with Sanofi through the launch of a newly created BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas. LAB150 awards its second drug discovery project from Canada’s largest research based Hospital, The University Health Network (UHN) Toronto, Canada, October 4, 2018 MaRS Innovation announced today the second project to be developed under their LAB150 partnership with Evotec. The project aims to develop a novel therapeutic approach to treat glaucoma, an irreversible neurodegenerative disease of the optic nerve which can lead to blindness. This project is derived from a decade of research investigating the molecular pathways underlying tissue damage and repair in the eye in the laboratory of Dr. Jeremy Sivak, Senior Scientist at UHN’s Krembil Research Institute, in Toronto. Evotec publishes DDup 7 – Kidney diseases 2.0 Hamburg, Germany, September 27, 2018 In this 7th DDup issue, we delve into the unique new kidney platforms poised to change the trajectory of kidney disease research and therapeutics development. Evotec and Almirall enter into research collaboration in the field of dermatological diseases Hamburg, Germany, September 17, 2018 Evotec AG and Almirall, S.A. today announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signalling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis. Evotec and Celgene enter partnership in the field of targeted protein degradation Hamburg, Germany, September 6, 2018 Evotec AG announced today that Evotec and Celgene Corporation (“Celgene”) have entered into a third long-term strategic drug discovery and development partnership in the field of targeted protein degradation. In this collaboration, Evotec and Celgene will leverage Evotec’s Panomics platform in order to identify drug targets which are traditionally difficult to track. Evotec’s Panomics platform applies in particular high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates on the basis of comprehensive cell biological profiles. Evotec AG listed in MDAX Hamburg, Germany, September 6, 2018 Evotec AG announced today that its shares will be included in the MDAX as of 24 September 2018 as announced by Deutsche Börse on 05 September 2018. This dual listing of the Evotec shares in both TecDAX and MDAX results from the rule changes regarding the inclusion of companies in the MDAX, SDAX and TecDAX. Evotec to attend upcoming investor conferences Hamburg, Germany, September 3, 2018 Evotec AG announced today that its management will be presenting and attending at the following conferences: Goldman Sachs 8th Annual Biotech Symposium, London, UK J.P. Morgan Cazenove Pan-European Small/Mid Cap Conference, London, UK Morgan Stanley 16th Annual Global Healthcare Conference, New York, USA Baader Investment Conference, Munich, Germany Berenberg and Goldman Sachs Seventh German Corporate Conference, Munich, Germany Cantor Global Healthcare Conference 2018, New York, USA Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington's disease Hamburg, Germany, August 30, 2018 Evotec AG today announced that CHDI Foundation, Inc. (“CHDI”) has extended its collaboration with Evotec through to 2023. Over this period, CHDI may fund up to 75 full-time scientists at Evotec. The collaboration was initiated in 2006 and has grown considerably over this period to fully utilise Evotec’s best-in-class integrated neuroscience platform. The extension of this collaboration is a further validation of Evotec’s investment in new technologies and capabilities in support of driving innovative drug discovery collaborations. Evotec and CENTOGENE sign global strategic partnership on drug discovery projects in rare genetic diseases Hamburg, Germany, August 27, 2018 Evotec AG today announced that CENTOGENE AG, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, and Evotec entered into a global strategic collaboration agreement for joint drug discovery projects, developing compounds to treat rare genetic diseases. Evotec and Novo Nordisk form strategic research alliance in diabetes and obesity Hamburg, Germany, August 22, 2018 Evotec AG today announced a strategic alliance with Novo Nordisk to discover and develop novel small molecule therapies to treat patients suffering from diabetes and obesity as well as co morbidities such as nonalcoholic steatohepatitis (“NASH”), cardiovascular diseases, and diabetic kidney disease. Evotec partner Haplogen enters into collaboration with Bayer Hamburg, Germany, August 14, 2018 Evotec AG announced today that Haplogen GmbH (“Haplogen”), a Vienna-based biotechnology company and collaboration partner of Evotec, has entered into a multi-year drug discovery and development collaboration with Bayer AG to identify new therapeutics with applications in pulmonary diseases such as chronic obstructive pulmonary disease (“COPD”). Evotec AG reports first half-year 2018 results and corporate updates Hamburg, Germany, August 9, 2018 Evotec AG today reported financial results and corporate updates for the first half of 2018. Evotec AG to report first half-year 2018 results on 09 August 2018 Hamburg, Germany, August 2, 2018 Evotec AG will report its financial results for the first half of 2018 on Thursday, 09 August 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. Evotec repays 50% of € 140 m acquisition loan Hamburg, Germany, July 31, 2018 Evotec AG announced today that it completes the repayment of 50% of the € 140 m debt bridge facility within the first year of being granted in context of the Aptuit acquisition in 2017. Effective August 2017, Evotec acquired Aptuit, a partner research organisation for integrated outsourced drug discovery and development, for € 253.2 m in cash. This acquisition was financed through existing cash reserves and a new € 140 m senior debt bridge facility. Evotec receives milestone payment for start of Phase II trial in its multi-target alliance with Bayer Hamburg, Germany, July 19, 2018 Evotec AG announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development for the treatment of chronic cough, resulting in a payment of € 4 m to Evotec. Evotec confirm closing of transaction with Sanofi to accelerate infectious disease research and development Hamburg, Germany, July 3, 2018 Evotec AG today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious disease research portfolio, has been successfully closed with effect from 01 July 2018. Evotec achieves second milestone in diabetes alliance with Sanofi Hamburg, Germany, June 25, 2018 Evotec AG today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached its second beta cell therapy milestone, resulting in a payment of € 3 million to Evotec. This milestone was triggered after Evotec met pre-agreed critical success criteria for a potential manufacturing process for generation of human induced pluripotent stem cell (iPSC)-derived beta cells, including the demonstration of upscaling potential and suitability of the cell product for encapsulated beta cell function in diabetes models. Resolutions of the Annual General Meeting 2018 of Evotec AG Hamburg, Germany, June 20, 2018 Evotec AG today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2018 with the required majorities. Evotec and Sanofi sign definitive agreement to combat infectious diseases Hamburg, Germany, June 18, 2018 Evotec AG today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives. This successfully seals the exclusive negotiations between the two companies and completion of the required legal social process, initiated on 08 March 2018. Evotec forms academic BRIDGE LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research Center Hamburg, Germany, May 31, 2018 Evotec AG announced today the formation of the LAB591 academic BRIDGE with Arix Bioscience plc (“Arix”, London Stock Exchange: ARIX ) and the Fred Hutchinson Cancer Research Center (“Fred Hutch”). LAB591 aims to accelerate research discoveries at Fred Hutch and leverage these discoveries to form new companies focused on cancer and infectious disease drug development. Evotec and Celgene expand iPSC collaboration to include additional cell lines Hamburg, Germany, May 29, 2018 Evotec AG announced today that the Company will receive a $ 6 m payment from Celgene following Celgene’s decision to expand the collaboration to include additional cell lines. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Evotec expands iPSC platform with licence from ID Pharma Hamburg, Germany, May 23, 2018 Evotec AG today announced that it has expanded its iPSC platform through a licence agreement with ID Pharma. The non-exclusive licence enables Evotec to both work with and differentiate induced pluripotent stem cells (“iPSC”) produced with ID Pharma’s Sendai virus (“SeV”) vector technology. Evotec and Celgene enter into strategic oncology partnership Hamburg, Germany, May 21, 2018 Evotec AG announced today that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology. Evotec reports first quarter 2018 results and provides corporate update Hamburg, Germany, May 9, 2018 Evotec AG today reported financial results and provided corporate updates for the first quarter of 2018. Evotec and Carna Biosciences collaborate on INDiGO platform Hamburg, Germany, May 8, 2018 Evotec AG today announced a strategic collaboration with Carna Biosciences, Incorporated (“Carna”). Carna will access Evotec’s INDiGO platform to accelerate the development of its programme CB-1763, which is being developed for the treatment of blood cancer, through to the submission of an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration. Evotec to present at upcoming investor conferences Hamburg, Germany, May 4, 2018 Evotec AG announced today that its management will be presenting at the Deutsche Bank 43rd Annual Health Care Conference in Boston, USA, at the Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, USA, at the Berenberg USA Conference 2018 in Tarrytown, USA, at the Jefferies 2018 Global Healthcare Conference in New York, USA, and at the dbAccess Berlin Conference in Berlin, Germany. Evotec expands CRISPR-based technology offering with licence from ERS Genomics Hamburg, Germany, May 2, 2018 Evotec AG today announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene editing, thereby complementing and expanding its existing service offering in the CRISPR gene editing space. The new licence from ERS Genomics Limited complements and expands Evotec’s existing CRISPR licences through the Broad Institute with gene editing technology from Emmanuelle Charpentier and others. Evotec AG to report first quarter 2018 results on 09 May 2018 Hamburg, Germany, May 2, 2018 Evotec AG will report its financial results for the first quarter of 2018 on Wednesday, 09 May 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for the fiscal year 2018. The conference call will be held in English. Excelling Together for the Benefit of Women Suffering from Endometriosis Hamburg, Germany, April 25, 2018 Five years after initiating our endometriosis alliance with Bayer, we draw some very important lessons from one of our key performance-based alliances – and share our insights. Evotec and Bayer advance third endometriosis programme into Phase I clinical development Hamburg, Germany, April 18, 2018 Evotec AG announced today that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive condition that affects approximately 176 million women worldwide. Evotec forms collaboration with Petra Pharma on INDiGO platform Hamburg, Germany, April 11, 2018 Evotec AG announced today a strategic collaboration with Petra Pharma Corporation (“Petra”). Through the collaboration, Petra will access Evotec’s INDiGO platform to accelerate the development of its lead programme Petra-01, which is being developed for a range of oncological indications, through to the submission of an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration by the close of 2018. Evotec AG fiscal year 2017 results: Leading external innovation Hamburg, Germany, March 28, 2018 Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2017. Evotec launches INDiGO®, a unique integrated drug development solution for accelerating early drug candidates into the clinic Hamburg, Germany, March 26, 2018 Evotec AG has launched its accelerated drug development service INDiGO®. With the launch of INDiGO®, Evotec’s expertise and capabilities are uniquely combined under one roof to deliver better drug candidates to patients faster and more efficiently than standard industry approaches. Evotec AG to report fiscal year 2017 results on 28 March 2018 Hamburg, Germany, March 21, 2018 Evotec AG will report its financial results for 2017 on Wednesday, 28 March 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2018. The conference call will be held in English. Evotec and Sanofi in exclusive talks to create an Evotec-led infectious disease open innovation R&D platform Hamburg, Germany, and Paris, France, March 8, 2018 Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France. Evotec to attend upcoming investor conferences Hamburg, Germany, March 7, 2018 Evotec AG announced today that its management will be presenting at upcoming investor conferences Novo Holdings announce launch of “REPAIR” and formation of Scientific Selection Board Hamburg, Germany, February 28, 2018 According to a press release published today by Novo Holdings, a new fund has been launched focused on new approaches to fight against antimicrobial resistance. Evotec and MaRS Innovation announce first funded project under LAB150 BRIDGE Hamburg, Germany, and Toronto, Canada, February 15, 2018 Evotec AG and MaRS Innovation announced today that they have identified the first project to be developed under their LAB150 partnership. Evotec and APEIRON achieve first milestone in immuno-oncology alliance with Sanofi Hamburg, Germany and Vienna, Austria, January 8, 2018 Evotec AG and APEIRON Biologics AG, a company focused on cancer immunotherapy, announced today that the companies received the first milestone payment from Sanofi under a 3 party alliance signed in August 2015. Evotec to attend upcoming investor conferences Hamburg, Germany, January 3, 2018 Evotec AG announced today that its management will be presenting at upcoming investor conferences 2017 Evotec enters into research collaboration with CRTD to discover novel therapies for retinal diseases Hambuirg, Germany, December 13, 2017 Evotec AG today announced that it has entered into a research collaboration with the Center for Regenerative Therapies TU Dresden ("CRTD") to discover novel small molecule candidates for retinal diseases. Evotec's Academic Bridge LAB282 with Oxford University celebrating one year of impact Hamburg, Germany, December 11, 2017 Evotec AG announced today that LAB282, the £ 13 m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec, is celebrating its first year of operation after successfully accelerating 12 drug discovery and development projects at the University. Ncardia and Evotec Entered a Licencing Agreement for Disease Modelling Using iPS Cells Hamburg, Germany, December 4, 2017 Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced today that they entered into a global non-exclusive IP licensing agreement with Evotec Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim Hamburg, Germany, December 1, 2017 Evotec AG announced today that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues of EUR 2.00 m to Evotec. Carrick Therapeutics announces first patient dosed in phase 1 clinical trial of its oral CDK7 inhibitor: CT7001 Hamburg, Germany, November 21, 2017 Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, today announced that the first patient has been dosed in the phase 1 clinical programme of CT7001 Evotec to attend upcoming investor conferences Hamburg, Germany, November 9, 2017 Evotec AG announced today that its management will be presenting at upcoming investor conferences Evotec AG announces first nine-month 2017 results and corporate update Hamburg, Germany, November 8, 2017 Evotec AG today reported financial results and corporate updates for the first nine months of 2017. Evotec joins forces with academic leaders to accelerate drug discovery in kidney diseases and build "NEPLEX" Hamburg, Germany, November 6, 2017 Evotec AG today announced a strategic collaboration on microfluidics technology including induced pluripotent stem cell ("iPSC") differentiation with leading academic institutions in the UK and Italy to accelerate the discovery of novel drugs to treat kidney diseases. Evotec AG to report first nine-month 2017 results on 08 November 2017 Hamburg, Germany, November 2, 2017 Evotec AG will report its financial results for the first nine months of 2017 on Wednesday, 08 November 2017. Evotec and Tesaro enter strategic partnership to discover novel immuno-oncology agents Hamburg, Germany, October 26, 2017 Evotec AG and TESARO, Inc. today announced a three-year integrated drug discovery collaboration to discover and develop novel small molecule product candidates against an undisclosed immuno-oncology (IO) target. Evotec achieves first milestone in neurodegeneration alliance with Celgene Hamburg, Germany, October 10, 2017 Evotec AG announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec. Evotec invests in Exscientia to advance AI-driven drug discovery Hamburg, Germany, September 28, 2017 Evotec AG and Exscientia Ltd ("Exscientia") today announced that Evotec has made a EUR 15 m investment to take a minority stake in Exscientia. Evotec and MaRS Innovation establish Academic Bridge "LAB150" in Toronto Hamburg, Germany, September 14, 2017 Evotec AG and MaRS Innovation ("MI") today announced the launch of "LAB150". European Investment Bank supports Evotec´s Innovate strategy with € 75 m loan Hamburg, Germany, September 8, 2017 Evotec AG and the European Investment Bank ("EIB") announced today that the EIB has granted Evotec an unsecured loan facility of up to EUR 75 m to support Evotec's Innovate strategy. Evotec and ABIVAX enter into strategic collaboration to develop novel antiviral agents Hamburg, Germany, September 7, 2017 Evotec AG and ABIVAX today announced a strategic collaboration to discover and develop novel treatments for multiple serious viral infectious diseases. Evotec to attend upcoming Investor Conferences Hamburg, Germany, September 6, 2017 Evotec AG announced today that its management will be presenting at upcoming investor conferences. Evotec completes acquisition of Aptuit Hamburg, Germany, August 16, 2017 Evotec AG today announced that, effective mid-August 2017, it has successfully completed the acquisition of Aptuit as announced in detail on 30 July 2017. Evotec announces first half year 2017 results and corporate update Hamburg, Germany, August 10, 2017 Evotec AG today reported financial results and corporate updates for the first half of 2017. Evotec and Fraunhofer IME-SP sign strategic collaboration on iPSC technology Hamburg, Germany, August 3, 2017 Evotec AG today announced a strategic collaboration on induced pluripotent stem cell ("iPSC") technology with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, ScreeningPort. Evotec AG to report first half-year 2017 results on 10 August 2017 Hamburg, Germany, August 3, 2017 Evotec AG will report its financial results for the first half of 2017 on Thursday, 10 August 2017. Evotec to acquire Aptuit, expanding leadership in external innovation Hamburg, Germany, July 30, 2017 Evotec AG and Aptuit announced today that they have entered into a definitive agreement under which Evotec will acquire Aptuit for $ 300 m. Evotec expands collaboration with STORM Therapeutics on its RNA epigenetic platform Hamburg, Germany, July 27, 2017 Evotec AG announced today an integrated drug discovery collaboration with STORM Therapeutics ("STORM") to develop new small molecule epigenetic drugs for oncology and other therapeutic areas. Evotec and Bayer advance endometriosis programme into Phase I clinical development and extend alliance Hamburg, Germany, July 24, 2017 Evotec AG announced today that its multi-target endometriosis alliance with Bayer has advanced a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec. Evotec received funding from IFB Hamburg to identify antibody-mediated t-cell immunotherapies Hamburg, Germany, July 6, 2017 Evotec AG announced today that the Company has been awarded a 'Programm für Innovation' ("PROFI") grant for a period of two years from the Hamburgische Investitions- und Förderbank Evotec expands iPSC drug discovery leadership through strategic collaboration with Censo Biotechnologies Hamburg, Germany, June 28, 2017 Evotec AG today announced a collaboration with Censo Biotechnologies Ltd. ("Censo") to source and provide patient-derived induced pluripotent stem cells ("iPSC") to support Evotec's broad iPSC platform. LAB282 accelerates with second round funding Hamburg, Germany, June 22, 2017 Evotec AG announced today that LAB282, the drug discovery BRIDGE between Oxford University, has made its second round of awards to support promising life sciences ideas emerging from the University. Evotec announces strategic investment in Facio Therapies to support development of novel FSHD therapy Hamburg, Germany, June 20, 2017 Evotec AG announced today that it will make a strategic investment as part of Facio Therapies' ("Facio") 2017 funding round together with Australian, European and North American members of the Facioscapulohumeral dystrophy ("FSHD") community (Total volume: EUR 4.8 m). Evotec receives European Mediscience Award for 'Company of the Year' Hamburg, Germany, June 16, 2017 Evotec AG was awarded the European Mediscience Award for “Company of the Year”. Evotec joins NURTuRE consortium to mine unique kidney disease patient biobank Hamburg, Germany, June 14, 2017 Evotec AG today announced that it has joined the NURTuRE consortium to drive kidney disease focused drug discovery based on patient derived-data. Resolutions of the Annual General Meeting 2017 of Evotec AG Hamburg, Germany, June 14, 2017 Evotec AG today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting, which took place today, with the required majority. Forge Therapeutics and Evotec present first efficacy data for Lpxc inhibitor in uti model at ASM MICROBE 2017 Hamburg, Germany, June 2, 2017 Forge Therapeutics and Evotec present first efficacy data for Lpxc inhibitor in uti model at ASM MICROBE 2017 Evotec receives pre-clinical milestone as part of its Endometriosis Alliance with Bayer Hamburg, Germany, May 22, 2017 Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another significant pre-clinical milestone, triggering a payment of approx. EUR 5 m to Evotec for the transition of a programme into pre-clinical development for the treatment of endometriosis. Evotec to attend three upcoming investor conferences Hamburg, Germany, May 16, 2017 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at upcoming investor conferences Evotec announces first quarter results 2017 and corporate update Hamburg, Germany, May 10, 2017 Evotec AG today reported financial results and corporate updates for the first quarter of 2017. Evotec achieves first milestone in Diabetes alliance with Sanofi Hamburg, Germany, April 5, 2017 Evotec AG today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached an important milestone, triggering a payment of EUR 3.0 m to Evotec, for achieving pre-clinical proof-of-concept. Evotec´s partner Forge Therapeutics receives prestigious Carb-X research award Hamburg, Germany, March 31, 2017 Evotec AG today announced that its partner Forge Therapeutics ("Forge") has received a research award from CARB-X (Combating Antibiotic Resistant Bacteria) of $ 8.8 m to advance its novel Gram-negative antibiotic programme targeting LpxC for the treatment of bacterial infections. Evotec fiscal year results 2016: Leading innovation efficiency & First-in-class drug discovery Hamburg, Germany, March 28, 2017 Evotec AG today announced its financial results and corporate updates for the fiscal year ended 31 December 2016. Great story - Short film Hamburg, Germany, March 3, 2017 Evotec AG and Business France today released their short film about Evotec’s research site in Toulouse, France, under the headline: “Evotec found Business in France – Great story, short film”. Evotec AG: 'LAB282' awarded first projects Hamburg, Germany, February 21, 2017 Evotec AG is pleased to announce that LAB282, the £ 13 m (over EUR 15 m) drug discovery partnership with Oxford University, has made its first wave of awards, backing projects targeting cardiovascular diseases and infectious diseases. Novo A/S becomes new long-term strategic shareholder in Evotec Hamburg, Germany, February 9, 2017 Evotec AG today announced that it resolved on a capital increase from its authorised capital against cash. Evotec will issue 13,146,019 new shares to Novo A/S (Denmark). Novo A/S is the independent holding company for the Novo Group. Cyprotex, an Evotec company, expands into new UK facility at Alderley Park Hamburg, Germany, January 26, 2017 Evotec AG today announced that Cyprotex, a company wholly owned by Evotec AG, has completed the relocation of its UK operations from Macclesfield to Alderley Park. Evotec enters into an integrated drug discovery collaboration with Asahi Kasei Pharma (Japan) Hamburg, Germany, January 19, 2017 Evotec AG today announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan. Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics Hamburg, Germany, January 17, 2017 Evotec AG and MaRS Innovation today announced the launch of Fibrocor Therapeutics LP ("Fibrocor"), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases. Haplogen´s novel antiviral target partnered with Evotec published in 'Nature' Hamburg, Germany, January 12, 2017 Evotec AG today announced a promising research result in the field of picornaviruses published in a scientific article by Dr Thijn Brummelkamp, the co-founder of Haplogen GmbH, a biotech company based in Vienna, Austria, that develops antiviral therapeutics in a co-owned partnership with Evotec. Evotec and Eternygen to develop novel metabolic disease therapy Hamburg, Germany, January 9, 2017 Evotec AG announced today that it will extend its existing relationship with Eternygen GmbH ("Eternygen") by becoming an investor in addition to being a pre-clinical drug discovery partner. 2016 Evotec and Celgene enter into drug discovery collaboration for neurodegenerative diseases Hamburg, Germany, December 15, 2016 Evotec AG announced today that Evotec and Celgene Corporation have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases. Evotec completes acquisition of Cyprotex PLC Hamburg, Germany, December 15, 2016 Evotec AG today announced the successful closing of the acquisition of 100% shares in Cyprotex PLC, a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in the UK. Evotec and Forge Therapeutics form strategic 'superbug' alliance Hamburg, Germany, December 9, 2016 Evotec AG today announced a strategic alliance with Forge Therapeutics, Inc. ("Forge") to advance its novel Gram-negative antibiotic programme targeting "LpxC" for the treatment of bacterial infections including those caused by drug resistant 'superbugs'. Evotec and Merck enter into agreements to collaborate on target discovery technologies Hamburg, Germany, November 30, 2016 Evotec AG today announced the signing of a set of collaboration agreements with the life science business of Merck, which will combine Merck's portfolio of genome editing technologies with Evotec's versatile screening platforms and disease expertise. Evotec and Oxford create novel Partnership called 'LAB282' Hamburg, Germany, November 10, 2016 Evotec AG today announced a novel strategic partnership with the University of Oxford, Oxford University Innovation Ltd, OUI (the university's research commercialisation company) and Oxford Sciences Innovation, OSI (the world's largest IP investment company dedicated to a single university) aimed at accelerating the translation of basic biomedical research from Oxford into new therapeutics. Evotec AG reports results of first nine months of 2016 Hamburg, Germany, November 10, 2016 Evotec AG today reported financial results and corporate updates for the first nine months of 2016. Evotec announces its intent to acquire Cyprotex PLC Hamburg, Germany, October 26, 2016 Evotec AG today announced that it has made an offer to acquire Cyprotex PLC ("Cyprotex", AIM: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK. Evotec and UCB sign multi-year CNS pharmacology agreement Hamburg, Germany, October 20, 2016 Evotec AG today announced a collaboration with UCB to provide a broad range of in vitro pharmacology services. Evotec and Carrick Therapeutics build strategic alliance Hamburg, Germany, October 4, 2016 Evotec AG announced today that in line with its strategy to participate in promising corporate formations it will deepen its already existing relationship with Carrick. Evotec receives further important pre-clinical milestone in endometriosis alliance with Bayer Hamburg, Germany, September 29, 2016 Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another key pre-clinical milestone for the transition of a project from the alliance portfolio into pre-clinical development. Evotec enters into strategic multi-target alliance with C4X Discovery Hamburg, Germany, September 28, 2016 Evotec AG today announced a multi-target collaboration with C4X Discovery Holdings plc ("C4XD"). Evotec enters into a research collaboration with Inserm in oncology Hamburg, Germany, September 22, 2016 Evotec AG announced today that the Company has entered into a research collaboration with Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research ("Inserm"). Evotec and Bayer partner to develop new treatments to fight kidney diseases Hamburg, Germany, September 21, 2016 Evotec AG today announced that Evotec and Bayer have entered into a five-year, multi-target research partnership in kidney disease. Evotec AG reports results of first half of 2016 Hamburg, Germany, August 10, 2016 Evotec AG today reported financial results and corporate updates for the first half of 2016. Evotec achieves clinical development milestone as part of its multi-target alliance with Bayer in endometriosis Hamburg, Germany, August 4, 2016 Evotec AG announced today that it has reached a milestone from Bayer for the progression of a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec. Evotec awarded contract from Antibiotic Research UK to begin integrated drug discovery collaboration Hamburg, Germany, July 11, 2016 Evotec AG announced today a collaboration with Antibiotic Research UK ("ANTRUK") to identify alternative means of treating infections that are resistant to currently available antibiotics. Evotec enters license agreement for access to CRISPR-Cas9 gene editing technology Hamburg, Germany, July 6, 2016 Evotec AG announced today that the Company has entered into a non-exclusive licence agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology. Evotec and Ellersbrook join forces to accelerate TargetNASH Hamburg, Germany, June 29, 2016 Evotec AG announced today that the investment company Ellersbrook GmbH & Co. KG, ("Ellersbrook"), Germany, will invest into Evotec's internal TargetNASH programme. Resolutions of the Annual General Meeting of Evotec AG Hamburg, Germany, June 14, 2016 APPROVAL OF ALL AGENDA ITEMS WITH THE REQUIRED MAJORITYACTIONS OF MANAGEMENT BOARD AND SUPERVISORY BOARD APPROVEDAPPOINTMENT OF ERNST & YOUNG GMBH WIRTSCHAFTSPRÜFUNGSGESELLSCHAFT AS AUDITORNEW RESOLUTION AUTHORISING THE ... Evotec receives European Mediscience Award for ‘Best Communication’ Hamburg, Germany, June 10, 2016 Hamburg, Germany, 10 June 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) was awarded the European Mediscience Award for best communication. The award was presented to Gabriele Hansen, VP Corporate ... Evotec extends integrated drug discovery alliance with Genentech Hamburg, Germany, May 24, 2016 Evotec AG today announced that Genentech, a member of the Roche Group, has extended its integrated drug discovery alliance with Evotec for a further three years to discover novel small molecule therapeutics. Evotec AG reports results of first quarter 2016 Hamburg, Germany, May 10, 2016 Evotec AG today reported financial results and corporate updates for the first quarter of 2016. Evotec to report First Quarter 2016 Results on 10 May 2016 Hamburg, Germany, May 3, 2016 Hamburg, Germany - 03 May 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) will report its financial results for the first quarter of 2016 on Tuesday, 10 May 2016. The Company is going to hold a ... Evotec and Exscientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics Hamburg, Germany, April 26, 2016 Evotec AG and Exscientia Ltd (Dundee, UK) today announced a collaboration with the objective to discover and develop first-in-class bispecific small molecule immuno-oncology therapies. Evotec and Pierre Fabre sign multi-year compound management agreement Hamburg, Germany, April 19, 2016 Evotec AG today announced a multi-year compound management agreement with Pierre Fabre Laboratories, the 2nd largest private French pharmaceutical group. Evotec spins off auto-immune disease company as 'Topas Therapeutics GmbH' Hamburg, Germany, March 22, 2016 Evotec AG today announced the formation of a spin-off company in the field of nanoparticle-based therapeutics to treat immunological disorders. Evotec FY 2015: Excellent execution meets first-in-class innovation Hamburg, Germany, March 22, 2016 Evotec AG today announced its financial results for the fiscal year ended 31 December 2015. Evotec AG: Fiscal year 2015 results presentation on 22 March 2016 Hamburg, Germany, March 15, 2016 Hamburg, Germany - 15 March 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) will report its financial results for 2015 on Tuesday, 22 March 2016. The Company is going to hold a conference call to ... Evotec achieves milestone in collaboration with Padlock Therapeutics Hamburg, Germany, March 10, 2016 Evotec AG today announced the achievement of a key pre-clinical milestone in the ongoing alliance with its research partner Padlock Therapeutics, Inc. ("Padlock"). Evotec to present at IR conference Hamburg, Germany, March 3, 2016 Hamburg, Germany - 03 March 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its CEO, Dr Werner Lanthaler, will present at the BioCapital Europe 2016 in Amsterdam, The Netherlands, ... The preclinical clinical interface: A key to translational success in Oncology Hamburg, Germany, February 25, 2016 Evotecs nächstes Webinar “The preclinical clinical interface: A key to translational success in Oncology” findet am Donnerstag, den 10. März 2016 um 10.00 Uhr EST / 15.00 Uhr GMT statt und wird unter anderem ... Evotec awarded grant from The Michael J. Fox Foundation for Parkinson's Research Hamburg, Germany, February 2, 2016 Evotec AG today announced that it has been awarded a research grant from The Michael J. Fox Foundation ("MJFF") to further develop Evotec's TargetaSN (Targetalpha-synuclein) programme for the treatment of Parkinson's disease. Evotec achieves important milestone in TargetAD collaboration with Janssen in Alzheimer's disease Hamburg, Germany, January 12, 2016 Evotec AG today announced the achievement of an important milestone in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. ("Janssen") for the transition of a project into further drug discovery process. Evotec and UCB sign multi-year sample management agreement Hamburg, Germany, January 7, 2016 Evotec AG today announced an EVT Execute collaboration aimed at providing a complete solution to UCB's global sample management requirements. 2015 Evotec and Spero Therapeutics extend collaboration to develop novel antibacterials Hamburg, Germany, December 15, 2015 Evotec AG today announced an extension of an existing collaboration with Spero Therapeutics, based in Cambridge, Massachusetts, aimed at discovering and developing new and ground-breaking therapeutics for Gram-negative bacteria to treat serious infections and address the growing threat to global public health resulting from antibiotic resistance. Evotec receives important pre-clinical milestones as part of its multi-target alliance with Bayer HealthCare Hamburg, Germany, December 10, 2015 Evotec AG announced today that its multi-target collaboration with Bayer HealthCare has reached two important pre-clinical milestones for the transition of two projects from the alliance portfolio into late-stage discovery and pre-clinical development for the treatment of endometriosis. Huntington’s disease and the hope for a treatment Hamburg, Germany, November 20, 2015 Hamburg, Germany - 20 November 2015: Evotec announced that Charles Sabine, former Emmy-awarded NBC News journalist and a high-profile spokesman for the global Huntington’s disease community, gave a lecture on “Why ... Evotec AG reports results of the first nine months of 2015 Hamburg, Germany, November 10, 2015 - STRONG GROWTH IN REVENUES AND PROFITS - THREE MAJOR EVT INNOVATE DEALS CONCLUDED - REVENUE GUIDANCE RAISED ON 15 SEPTEMBER 2015 Hamburg, Germany - 10 November 2015: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: ... Evotec and Beyond Batten Disease Foundation collaborate to advance emerging therapies to fight juvenile Batten Disease Hamburg, Germany, October 20, 2015 Evotec AG today announced an EVT Execute collaboration with Beyond Batten Disease Foundation aimed at discovering and developing new treatments for juvenile Batten disease, a rare, fatal autosomal recessive neurodegenerative disorder. Evotec awarded multi-year contract to manage National Cancer Institute Chemical Biology Consortium Screening Libraries Center Hamburg, Germany, October 5, 2015 Evotec AG today announced it has entered into a multi-year compound management agreement with the U.S. National Cancer Institute, Department of Health and Human Services. Evotec AG increases its revenue guidance for 2015 Hamburg, Germany, September 15, 2015 Evotec AG today announced that it increases its financial guidance for the current year. Evotec enters into licence and collaboration agreement with Pfizer Inc. in tissue fibrosis Hamburg, Germany, September 9, 2015 Evotec AG today announced that it has signed an agreement on a four-year research collaboration with Pfizer Inc. Evotec publishes update of its DDup Special Edition – Drug discovery services Hamburg, Germany, September 4, 2015 Hamburg, Germany - 04 September 2015: Evotec AG today published its updated DDup Special edition “Drug discovery services”. This new edition outlines Evotec’s drug discovery platforms including new capacities, ... Evotec and CHDI Foundation expand ongoing collaboration to fight Huntington's disease using Evotec's expanded capabilities and footprint Hamburg, Germany, September 2, 2015 Evotec AG today announced that CHDI Foundation, Inc. has extended and expanded its collaboration with Evotec through to August 2018. Evotec AG reports results of first half of 2015 Hamburg, Germany, August 12, 2015 Evotec AG today reported financial results and corporate updates for the first half of 2015. Evotec, Apeiron Biologics and Sanofi jointly develop novel small molecule-based cancer immunotherapies Hamburg, Germany, August 10, 2015 Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, today announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies. Sanofi and Evotec align forces to develop next generation therapies in diabetes Hamburg, Germany, August 7, 2015 Evotec AG and Sanofi today announced a strategic collaboration in the field of diabetes. Evotec enters innovative research initiative with Gladstone Institutes and Dolby Family Ventures in Alzheimer's Disease Hamburg, Germany, July 24, 2015 Evotec AG today announced that it has become part of a research initiative between a newly established for-profit company of the Gladstone Institutes called Cure Network Ventures, Inc. and Dolby Family Ventures. Evotec's partner Roche provides initial update from Phase IIb trial in Alzheimer's disease Hamburg, Germany, June 30, 2015 Evotec AG was updated today by its partner Roche on the initial results of the Phase IIb trial with Sembragiline, a MAO-B inhibitor for the treatment of Alzheimer's disease. Resolutions of the Annual General Meeting of Evotec AG Hamburg, Germany, June 9, 2015 - Approval of all agenda items with the required majority - Actions of Management Board and Supervisory Board approved - New Supervisory Board member elected: Dr Elaine Sullivan - Contingent capital for the issue of subscription ... Evotec AG reports results of first quarter 2015 Hamburg, Germany, May 12, 2015 - VERY STRONG START TO 2015: 22% GROWTH OF GROUP REVENUES, MAINLY DRIVEN BY EVT EXECUTE - MAJOR MULTI-COMPONENT STRATEGIC ALLIANCE WITH SANOFI CLOSED- FULL-YEAR REVENUE GUIDANCE RAISED Hamburg, Germany - 12 May 2015: ... Facio partners with Evotec and initiates FSHD drug discovery programme Hamburg, Germany, April 29, 2015 Evotec AG and Facio Therapies announced today that they have entered into an agreement aimed at the identification of compounds showing activity as a potential treatment to stop the progression of FSHD, a muscle wasting disease. Asahi Kasei Pharma selects Evotec as its partner for ion channel drug discovery Hamburg, Germany, March 26, 2015 Evotec AG today announced it has entered into a multi-target screening collaboration on several ion channel targets, with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan. Evotec FY 2014: Strong performance in EVT Execute and acceleration of EVT Innovate Hamburg, Germany, March 24, 2015 Evotec AG today announced its financial results for the fiscal year ended 31 December 2014. Evotec and Sanofi sign definitive agreement for major multi-component strategic alliance Hamburg, Germany, March 20, 2015 Evotec AG today announced that a definitive agreement for a major multi-component strategic alliance over the next five years has been signed with Sanofi. Second Genome and Evotec to collaborate in microbiome discovery and development Hamburg, Germany, March 13, 2015 Evotec AG and Second Genome, Inc. today announced a collaboration in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. Evotec and C4XD enter collaboration to identify pre-clinical development candidates for stress-related addictive disorder programme Hamburg, Germany, January 19, 2015 Evotec AG today announced a research collaboration with C4X Discovery Holdings plc to optimise Orexin-1 selective inhibitors discovered through C4XD's unique NMR technology. Evotec achieves further milestones in TargetAD collaboration with Janssen Hamburg, Germany, January 15, 2015 Evotec AG today announced the achievement of several small, but very important milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the identification and selection of novel targets from Evotec's TargetAD database and for the transition of targets into the drug discovery process. Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration Hamburg, Germany, January 7, 2015 Evotec AG and Padlock Therapeutics, Inc. announced today that they have successfully completed an initial goal in a programme focused on developing inhibitors of protein-arginine deiminases and have further extended the collaboration that was first signed in January 2014. 2014 Evotec and Ohio State to collaborate on novel cancer therapy Hamburg, Germany, December 22, 2014 Evotec AG today announced a research collaboration with the laboratories of Prof. Roger Briesewitz at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Achievement of multiple milestones in Evotec's drug discovery alliances Hamburg, Germany, December 18, 2014 Evotec AG disclosed today that it achieved multiple milestones in ongoing alliances with its strategic research partners. Evotec and Sanofi enter into exclusive negotiations for a major multi-component strategic collaboration Hamburg, Germany, December 2, 2014 Evotec AG announced today that it has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years. Evotec reports results of the first nine months of 2014 Hamburg, Germany, November 12, 2014 Evotec AG today reported financial results and corporate updates for the first nine months of 2014. Evotec receives milestone as part of its multi-target alliance with Bayer HealthCare Hamburg, Germany, September 30, 2014 Evotec AG announced today that its multi-target collaboration with Bayer HealthCare has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis. Evotec and its partners awarded public grants to develop new drug candidates to treat multiple sclerosis Hamburg, Germany, September 24, 2014 Evotec AG announced today that it has entered into three novel research projects for the treatment of Multiple Sclerosis supported by research funds from the German Federal Ministry of Education and Research. Evotec takes legal steps against Andromeda Biotech, Ltd. Hamburg, Germany, September 18, 2014 Evotec AG announced today after careful evaluation that it will take legal steps against Israel-based Andromeda Biotech, Ltd. to recover all Evotec claims and potential damages that result from recent incidents in relation to DiaPep277®. Evotec and the Jain Foundation expand collaboration: Start of multiple drug screening programmes Hamburg, Germany, September 15, 2014 Evotec AG and the Jain Foundation Inc. today announced that they have further extended and expanded the collaboration first signed in 2012 and extended last year. Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington's disease Hamburg, Germany, September 11, 2014 Evotec AG today announced that CHDI Foundation, Inc. has extended and restated its collaboration with Evotec through 2017. Evotec announces update on DiaPep277® Hamburg, Germany, September 8, 2014 Evotec AG was informed that US company Hyperion Therapeutics, Inc. is terminating the development of DiaPep277® for newly diagnosed Type 1 diabetes. Evotec’s motor neuron research team and members of the Management Board help raise awareness for ALS disease Hamburg, Germany, August 25, 2014 On Friday, the motor neuron research group took on the ALS Ice Bucket Challenge to help raise awareness for this rapidly progressive neurodegenerative disease. Evotec and Medicines For Malaria Venture announce a long-term compound management collaboration Hamburg, Germany, August 19, 2014 Evotec AG today announced the start of a multi-year compound management agreement between Evotec (US) Inc. and Medicines for Malaria Venture in support of MMV's Malaria and Pathogen Box initiatives. Evotec AG reports results of first half of 2014 Hamburg, Germany, August 12, 2014 Evotec AG today reported financial results and corporate updates for the first half of 2014. Evotec receives first milestones in TargetAD collaboration Hamburg, Germany, July 30, 2014 Evotec AG today announced the successful achievement of the first milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the identification and selection of three selected targets from the TargetAD database. Evotec publishes DDup 5 – Antibiotics Hamburg, Germany, July 24, 2014 Evotec AG today announced the publication of its fifth DDup edition. Evotec to collaborate with Fraunhofer in joint drug discovery programmes Hamburg, Germany, July 8, 2014 Evotec AG announced today an exclusive strategic collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in several disease areas through the combination of the relevant platforms of both organisations for internal and external drug discovery projects. Evotec receives European Mediscience Award for ‘Best Communication’ Hamburg, Germany, June 23, 2014 Evotec AG was awarded the European Mediscience Award for best communication at a celebratory dinner on Thursday, 19 June 2014, in London. Evotec receives milestone payment as part of its discovery alliance with Boehringer Ingelheim Hamburg, Germany, June 19, 2014 Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 1.0 m to Evotec. Resolutions of the Annual General Meeting of Evotec AG Hamburg, Germany, June 17, 2014 Evotec AG today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting. Evotec to establish an anti-infectives platform with the acquisition of Euprotec Ltd Hamburg, Germany, May 28, 2014 Evotec AG today announced the acquisition of all shares in Euprotec Ltd, a UK-based specialist contract research organisation. Evotec AG reports results of first quarter 2014 Hamburg, Germany, May 14, 2014 Evotec AG today reported financial results and corporate updates for the first quarter of 2014. Evotec and Eternygen enter collaboration to identify and develop novel metabolic disease therapy Hamburg, Germany, May 6, 2014 Evotec AG and Eternygen GmbH, a privately owned biopharmaceutical company, today announced a drug discovery collaboration to develop novel small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec's technology platform and broad expertise in drug discovery and pre-clinical development. Evotec receives first milestone in Roche biomarker collaboration Hamburg, Germany, April 24, 2014 Evotec AG today announced the successful achievement of a milestone in its biomarker alliance with Roche. Evotec and Debiopharm Group(TM) to collaborate on development of new treatment for cancer Hamburg, Germany, April 2, 2014 Evotec AG announced today a research collaboration and licensing deal with Debiopharm GroupTM Lausanne, Switzerland. Evotec and Convergence form integrated pain alliance Hamburg, Germany, March 31, 2014 Evotec AG today announced that it has entered into a research alliance with Panion Ltd, a subsidiary of Convergence Pharmaceuticals Holdings Ltd. Convergence is a UK company focused on the development of novel, high value analgesics to treat chronic pain. Evotec FY 2013: Execute on Innovate to create value Hamburg, Germany, March 25, 2014 Evotec AG today announced its financial results for the fiscal year ended 31 December 2013, which are in line with the revised expectations communicated in the fourth quarter 2013. Evotec acquires Bionamics GmbH to accelerate 'EVT Innovate' strategy Hamburg, Germany, March 24, 2014 Evotec AG today announced the acquisition of the Germany-based Bionamics GmbH. 2013 Evotec and Yale University to collaborate on cancer therapy Hamburg, Germany, December 17, 2013 Evotec AG today announced a research collaboration, TargetDBR (DNA Break Repair), with the laboratories of Prof. Peter Glazer and Prof. Ranjit Bindra at Yale School of Medicine. Evotec AG: Results of pre-clinical studies lead to reduction in revenues, nevertheless profitable and more than € 90 m cash for 2013 confirmed Hamburg, December 13, 2013 Evotec AG today announced that it is adjusting its guidance regarding Group revenues. Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim Hamburg, Germany, December 10, 2013 Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in November triggering revenues of € 4.0 m to Evotec. Evotec AG reports first nine months 2013 results Hamburg, Germany, November 12, 2013 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today reported financial results and corporate updates for the third quarter and first nine months of 2013 ending 30 September 2013. Evotec announces TargetAD collaboration with Johnson & Johnson Innovation to identify and develop novel Alzheimer's disease therapies Hamburg, Germany, November 8, 2013 Evotec AG today announced a collaboration with the Johnson & Johnson Innovation Center in California to identify new targets for Alzheimer's disease drug discovery and development. Evotec and The Leukemia & Lymphoma Society enter into a strategic research collaboration Hamburg, Germany, November 5, 2013 Evotec AG announced today that it has entered into an integrated research collaboration with The Leukemia & Lymphoma Society. Evotec achieves first milestones in multi-target deal with UCB Hamburg, Germany, October 28, 2013 Evotec AG today announced that it has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with UCB in the field of immunology. Evotec enters integrated alliance with AstraZeneca in kidney disease Hamburg, Germany, October 21, 2013 Evotec AG today announced that it has signed an agreement with AstraZeneca in the field of kidney diseases. Evotec publishes DDup 4 – Epigenetics Hamburg, Germany, October 18, 2013 Evotec AG today announced the publication of its fourth DDup edition. Evotec to hold R&D Day 2013 Hamburg, Germany, October 16, 2013 Evotec AG announced today that its R&D Day 2013 will take place on 22 October 2013 in New York City, USA. Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim Hamburg, Germany, October 15, 2013 Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of EUR 4.0 m to Evotec. Evotec and Harvard University to collaborate on exploration of enteroendocrine signals affecting key metabolic pathways Hamburg, Germany, October 10, 2013 Evotec AG today announced a second research collaboration, TargetEEM, with the laboratory of Doug Melton, Xander University Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Harvard Stem Cell Institute Scientific Co-Director and Howard Hughes Medical Institute Investigator. Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim Hamburg, Germany, September 30, 2013 Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of € 2.0 m to Evotec. Evotec publishes DDup Special Edition – Drug Discovery Services Hamburg, Germany, September 18, 2013 Evotec AG announces today the publication of a DDup Special Edition, which focuses on its drug discovery service offering. Evotec and Harvard Stem Cell Institute form CureMN collaboration to advance ALS research Hamburg, Germany, September 12, 2013 Evotec AG today announced a strategic partnership with the Harvard Stem Cell Institute to identify compounds that prevent or slow down the loss of motor neurons, which is characteristic of the human disease amyotrophic lateral sclerosis. Evotec raises EUR 30 m from Biotechnology Value Fund Hamburg, Germany, August 31, 2013 Evotec AG today announced a 9.9% increase of its share capital. Evotec and the Jain Foundation announce extension of research collaboration in skeletal muscular dystrophy diseases Hamburg, Germany, August 21, 2013 Evotec AG and the Jain Foundation today announced that they have extended and expanded their research collaboration leveraging Evotec's assay development and screening capabilities to support the Jain Foundation's goals of understanding and curing dysferlinopathy. Evotec AG reports H1 2013 results Hamburg, Germany, August 8, 2013 Evotec AG today reported financial results and corporate updates for the first half of 2013. Evotec and Dow AgroSciences announce collaboration on Cellular Target Profiling Hamburg, Germany, July 9, 2013 Evotec AG today announced that Evotec and Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, have entered into a research collaboration with the objective of leveraging Evotec's advanced chemical proteomics services to support compounds in development at Dow AgroSciences. Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim Hamburg, Germany, July 8, 2013 Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in June triggering revenues of EUR 1.5 m to Evotec. Evotec to realign Discovery Chemistry Operations Hamburg, Germany, July 8, 2013 Evotec AG today announced that it will close its Chemistry Operations in Thane, India. Resolutions of the Annual General Meeting of Evotec AG Hamburg, Germany, June 12, 2013 Shareholders of Evotec AG today approved the actions of the members of the Management Board and the Supervisory Board for the fiscal year 2012 at the Annual General Meeting. Evotec and Harvard University to collaborate on development of new class of antibacterials Hamburg, Germany, May 16, 2013 Evotec AG today announced a research collaboration with Harvard University aimed at discovering and developing novel anti-bacterial agents based on a highly validated target family involved in bacterial cell wall biosynthesis. Evotec Q1 2013: Driving Innovation Efficiency Hamburg, Germany, May 14, 2013 Revenues without milestones increased in the first quarter of 2013 by 5% compared to the first quarter of 2012- Q1 2013 revenues amounted to EUR 17.1 m (2012: EUR 20.1 m); up 5% compared to Q1 2012 revenues of EUR 16.2 m on a ... Dana-Farber's Belfer Institute for Applied Cancer Science and Evotec establish collaboration in oncology Hamburg, Germany, April 30, 2013 The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG today announced a research collaboration aimed at discovering and commercialising novel cancer treatments based on epigenetic drug mechanisms. Evotec expands compound management capability to East Coast of the United States Hamburg, Germany, April 29, 2013 Evotec AG today announced that Evotec (US) Inc. has executed a multi-year lease on a facility specifically designed to expand the offering of its Compound Management Services on the East Coast of the United States. New hormone to treat diabetes published in 'Cell' Hamburg, Germany, April 26, 2013 Evotec AG today announced an auspicious step in research from Harvard University. Evotec extends drug discovery alliance with Genentech Hamburg, Germany, April 22, 2013 Evotec AG today announced that it has extended its drug discovery alliance with Genentech, a member of the Roche Group, for three additional years. Forward step by step with Action Plan 2016 - Continued revenue growth - Significant pipeline progress Hamburg, Germany, March 26, 2013 Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2012. Corporate Update Hamburg, Germany, March 18, 2013 Evotec AG today announced that Dr Werner Lanthaler, Chief Executive Officer of Evotec, will resume his role as Chief Executive Officer of the Company with immediate effect after a period of leave due to health reasons. Evotec achieves milestone in drug discovery collaboration with Ono Pharmaceutical Co., Ltd. Hamburg, Germany, January 11, 2013 Evotec AG today announced that a compound identified and optimised in a research collaboration with Ono Pharmaceutical Co., Ltd. has been nominated to enter pre-clinical development, leading to the payment of an agreed milestone. Evotec and Yale University form Open Innovation Alliance Hamburg, Germany, January 9, 2013 Evotec AG today announced that it has entered into a strategic partnership with Yale University. Evotec expands collaboration with MedImmune, receives milestone payment Hamburg, Germany, January 7, 2013 Evotec AG today announced that it has expanded the scope of its collaboration with MedImmune, the global biologics arm of AstraZeneca, after hitting a key milestone. Evotec acquires Cell Culture Service GmbH Hamburg, Germany, January 3, 2013 Evotec AG today announced the acquisition of all shares in Cell Culture Service GmbH, a Hamburg-based company which supports the cell culture needs of a world-wide customer base of biotech and Pharmaceutical companies. Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy Hamburg, Germany, January 2, 2013 Evotec AG today announced that Evotec and Apeiron Biologics have entered into a research collaboration with the objective of developing immunomodulatory lead compounds for the treatment of cancer. 2012 Evotec announces NMDA antagonist license agreement Hamburg, Germany, December 17, 2012 Evotec AG today announced that it has entered into a license agreement with Janssen Pharmaceuticals, Inc. regarding its NR2B subtype selective NMDA-antagonist portfolio for development against diseases in the field of depression. Evotec enters biology collaboration with Probiodrug Hamburg, Germany, November 28, 2012 Evotec AG announced today that it has entered into a collaboration with Probiodrug AG, a privately owned biopharmaceutical company focused on the development of innovative drugs for the treatment of major age related diseases. Evotec Receives CIR (French Research Tax Credit) Accreditation Hamburg, Germany, November 23, 2012 Evotec AG today announced that it has received CIR accreditation for a three-year period from the French Ministry of Higher Education and Research. Evotec partners with Haplogen to develop drugs for infectious diseases Hamburg, Germany, November 15, 2012 Evotec AG and Haplogen GmbH have signed a collaboration agreement to discover and develop small molecules against viral infectious diseases. Evotec reports 8% revenue growth and a positive operating result of EUR2.9 m in the first nine months of 2012 Hamburg, Germany, November 8, 2012 Evotec AG today reported financial results and corporate updates for the third quarter and first nine months of 2012 ending 30 September 2012. Evotec extends ongoing collaboration with CHDI Foundation Hamburg, Germany, October 29, 2012 Evotec AG today announced that CHDI Foundation, Inc., a privately-funded not-for-profit research organisation dedicated to developing therapies for Huntington's disease, has extended its collaboration with Evotec until the end of 2015. Evotec CEO awarded 'Turnarounder of the Year 2012' Hamburg, Germany, October 29, 2012 Evotec AG announced today that Dr Werner Lanthaler, Chief Executive Officer of Evotec, was awarded the prize 'Turnarounder of the Year 2012'. Evotec receives Milestone in Drug Discovery Collaboration Hamburg, Germany, October 8, 2012 Evotec AG today announced that it has received a pre-clinical milestone from its Drug Discovery Collaboration with Novartis. Corporate Update Hamburg, Germany, October 4, 2012 Evotec AG today announced that Dr Werner Lanthaler, CEO of Evotec, will temporarily stand down from his role within the company due to health reasons. Multi-target alliance with Bayer Hamburg, Germany, October 1, 2012 Evotec AG today announced that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis. Evotec and Aspireo enter into strategic advisory agreement Hamburg, Germany, September 28, 2012 Evotec AG and Aspireo Pharmaceuticals Limited an Israeli biopharmaceutical company focused on the development of a novel somatostatin analogue, announced today that they have entered into a strategic advisory agreement for support in the development and partnering of Aspireo's Somatoprim. Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim Hamburg, Germany, September 26, 2012 Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.5 million to Evotec. NIH awards major contract to Evotec to Manage and Operate a Small Molecule Repository Hamburg, Germany, September 19, 2012 Evotec AG today announced that Evotec has entered into a multi-year compound management agreement with the National Institutes of Health, Department of Health and Human Services, for the operation of a Small Molecule Repository. Building innovation on the back of profitable growth Hamburg, Germany, August 8, 2012 Evotec AG today reported financial results and corporate updates for the second quarter and first half of 2012 ending 30 June 2012. CureBeta, a collaboration between Evotec and Harvard University enters strategic alliance with Janssen Pharmaceuticals Hamburg, Germany, July 10, 2012 Evotec AG today announced that it has licensed to Janssen Pharmaceuticals, Inc. a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells. Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received Hamburg, Germany, June 5, 2012 Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 4.0 million to Evotec. Evotec Becomes the First Contract Research Facility in Europe to Offer Agilent's RapidFire/MS Screening for Pharmaceutical Drug Discovery Hamburg, Germany, May 16, 2012 Evotec AG is proud to announce the addition of Agilent Technologies' RapidFire Mass Spectrometry analysis capabilities to their High Throughput Screening facilities in Hamburg. Evotec reports continued strong revenue growth in Q1 2012 Hamburg, Germany, May 10, 2012 Evotec AG today reported financial results and corporate updates for the first quarter of 2012. Evotec AG and 4-Antibody AG form strategic collaboration to innovate antibody selection Hamburg, Germany, May 9, 2012 Evotec AG and 4-Antibody AG today announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service. Evotec AG announces multi-year agreement with The United States Environmental Protection Agency (EPA) Hamburg, Germany, May 3, 2012 Evotec AG today announced that Evotec has entered into a multi-year compound management agreement with the United States EPA. Evotec grants exclusive rights on EVT 401 in China to Conba Pharmaceutical Hamburg, Germany, May 2, 2012 Evotec AG and Conba Pharmaceutical Co., Ltd. announced today the grant of a development and marketing license on EVT 401, a selective, small molecule P2X7 antagonist, for human indications with exception of ophthalmological, chronic obstructive pulmonary disease and endometriosis in China. Evotec and Active Biotech Extend and Expand Medicinal Chemistry Collaboration Hamburg, Germany, April 26, 2012 Evotec AG today announced that it has extended and expanded its medicinal chemistry collaboration with Active Biotech AB, to further advance an existing programme, which has entered the lead optimisation phase. Evotec publishes DDup 2 – neurodegenerative diseases Hamburg, Germany, April 24, 2012 Evotec AG today announced the publication of its second edition of DDup, which focuses on neurodegeneration diseases, major disorders with inadequate standards of care. Evotec FY 2011: Significant Growth and Focused Investments Drive Profitability and Innovation Hamburg, Germany, March 20, 2012 Evotec AG today reported financial results and corporate updates for the year ended 31 December 2011. Evotec and IR Pharma Establish Drug Discovery Alliance in the Field of Respiratory Hamburg, Germany, February 16, 2012 Evotec AG and IR Pharma today announced that they have entered into an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of Respiratory Diseases. Squeeze-out process for DeveloGen completed Hamburg, Germany, January 24, 2012 Evotec AG today announced the completion of the squeeze-out process to acquire all of the remaining shares of DeveloGen AG from its minority shareholders. Evotec and Harvard University Expand Strategic Alliance into Kidney Disease Hamburg, Germany, January 17, 2012 Evotec AG today announced a second strategic alliance with Harvard University, this time including Brigham and Women's Hospital aimed at discovering and developing new biomarkers and treatments in the field of kidney disease. Evotec Receives 4th Milestone Payment in 2011 as Part of its Discovery Alliance with Boehringer Ingelheim Hamburg, Germany, January 11, 2012 Evotec AG today announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 2.5 million to Evotec. 2011 Nine months results: Upside materialising Hamburg, Germany, November 10, 2011 Evotec AG today reported financial results and corporate updates for the first nine months of 2011. Two Milestones in Fragment-based Drug Discovery Alliance with Shionogi achieved Hamburg, Germany, October 27, 2011 Evotec AG today announced the achievement of specific success criteria in a multiple target drug discovery collaboration with Shionogi & Co Ltd. and the receipt of two milestone payments. Evotec and APEIRON Biologics start next project on the Cbl-b target Hamburg, Germany, October 20, 2011 Evotec AG and Apeiron Biologics AG today announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy. Second multi-target collaboration with UCB announced Hamburg, Germany, October 5, 2011 Evotec AG today announced that it has entered into a second multi year, multi target integrated drug discovery collaboration with UCB in the field of immunology. Acquisition of remaining 30% of Indian Joint Venture from DIL Hamburg, Germany, September 29, 2011 Evotec AG today announced that it has signed a Share Purchase Agreement to acquire the remaining 30% of equity of its Joint Venture with DIL Limited, India for €1.7M. Evotec and Roche agree to develop compound that could slow the progression of Alzheimer's disease Hamburg, Germany, September 5, 2011 Evotec AG and Roche AG announced today that they have entered into an exclusive worldwide agreement for the development and commercialization of Evotec's MAO-B inhibitor in patients with Alzheimer's disease. Pre-clinical Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received Hamburg, Germany, August 18, 2011 Evotec AG today announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 4 million to Evotec. P2X7 antagonist programme, EVT 401, to a top tier global animal health company partnered Hamburg, Germany, August 11, 2011 Evotec AG today announced that it has entered into a world-wide license and collaboration agreement with a top tier animal health company that intends to develop the proprietary Evotec compound EVT401, a selective, small molecule P2X7 antagonist, in the companion animal market. Evotec reports 34% revenue and profitable earnings growth; revenue guidance raised Hamburg, Germany, August 11, 2011 Evotec AG today reported financial results and corporate updates for the first half of 2011. Multi-target collaboration with UCB in neurodegenerative and neurological diseases announced Hamburg, Germany, July 7, 2011 Evotec AG today announced that it has entered into a three year integrated drug discovery collaboration with UCB to identify small molecule modulators of priority biological targets, selected by UCB, involved in CNS disorders. Milestone in an Ion Channel Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. achieved Hamburg, Germany, June 27, 2011 Evotec AG today announced the achievement of specific success criteria in an ion channel research collaboration with Ono Pharmaceutical Co., Ltd. and the receipt of a milestone payment. Evotec and Roche to jointly develop biomarkers in oncology Hamburg, Germany, June 24, 2011 Evotec AG and Roche today announced a collaboration in novel protein-activity based biomarkers for Roche's oncology drugs under development. Medicinal Chemistry Collaboration with Active Biotech Hamburg, Germany, June 6, 2011 Evotec AG today announced that it has entered into a medicinal chemistry collaboration with Active Biotech AB, following the successful conclusion of a High Throughput Screening campaign to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. Compound management business from Galapagos acquired Hamburg, Germany, June 1, 2011 Evotec AG and Galapagos NV today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, a Galapagos Company. Milestone received as Boehringer Ingelheim starts Phase I clinical trial in Pain Hamburg, Germany, May 31, 2011 Evotec AG today announced that a back-up compound in its strategic alliance with Boehringer Ingelheim has advanced into a Phase I clinical trial. Evotec will receive a milestone payment of EUR 2.0 million. Strategic Alliance with PsychoGenics entered to Provide Integrated CNS Drug Discovery Solutions Hamburg, Germany, May 25, 2011 Evotec AG today announced that it has entered into a strategic alliance with PsychoGenics Inc. to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies. Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated Hamburg, Germany, May 18, 2011 Evotec AG and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type selective NMDA antagonist EVT 101. Evotec reports 54% Q1 revenue growth and significant expansion of drug discovery alliance business Hamburg, Germany, May 12, 2011 Evotec AG today reported financial results and corporate updates for the first quarter of 2011. Twelfth Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received Hamburg, Germany, May 9, 2011 Evotec AG today announced that its research alliance with Boehringer Ingelheim has achieved a twelfth milestone triggering a payment of EUR 2.0 million to Evotec. Acquisition of Kinaxo Biotechnologies GmbH completed Hamburg, Germany, April 19, 2011 Evotec AG today announced that it has completed the acquisition of Kinaxo Biotechnologies GmbH, a privately held drug discovery alliance company supporting the development of targeted drugs. Full-Year 2010 Results: A good year with a strong start into 2011 Hamburg, Germany, March 24, 2011 Evotec AG today reported financial results and corporate updates for the year ended 31 December 2010. Evotec Establishes Research Collaboration With Harvard University and the Howard Hughes Medical Institute in Diabetes Research Hamburg, Germany, March 10, 2011 Evotec AG today announced the establishment of a research collaboration with Harvard University and the Howard Hughes Medical Institute aimed at discovering and developing new treatments in the field of diabetes. Evotec to Strengthen its Compound Collection through a Collaboration with ChemBridge Hamburg, Germany, February 15, 2011 Evotec AG today announced that it has entered into a collaboration with ChemBridge, to further enhance its screening library. Expanding its drug discovery platform with cutting-edge technologies Hamburg, Germany, February 9, 2011 Evotec AG today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs. Collaboration with Takeda Cambridge for Multi-target Hit Identification Hamburg, Germany, January 20, 2011 Evotec AG today announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and Protease targets involved in various CNS and Metabolic diseases. Milestone Payment received from Boehringer Ingelheim Hamburg, Germany, January 13, 2011 Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.0 million to Evotec. Evotec deregisters from the US Securities and Exchange Commission Hamburg, Germany, January 4, 2011 Evotec AG announced today that on 30 December 2010 it filed a Form 15F with the Securities and Exchange Commission to deregister and terminate its reporting obligations under the U.S. Securities Exchange Act of 1934 for its American Depositary Shares and its ordinary shares underlying the ADSs. 2010 Metabolic disease alliance with MedImmune Hamburg, Germany, December 15, 2010 Evotec AG today announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune, in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells. Collaboration on neurological disease target with Merck KGaA Hamburg, Germany, November 23, 2010 Evotec AG today announced that it has signed within the "NEU²-Consortium" framework and partially funded by the Federal Ministry of Education and Research, an agreement with Merck KGaA, Darmstadt, Germany, to develop pre-clinical candidates for an undisclosed neurological disease. Accelerated Positive Trend on Evotec's Revenues and Profits Hamburg, Germany, November 11, 2010 Evotec AG today reported financial results and a corporate update for the first nine months of 2010. License and collaboration agreement with Jingxin Pharma for EVT 201 Hamburg, Germany, October 28, 2010 Evotec AG today announced that it has entered into a license and collaboration agreement with Zhejiang Jingxin Pharmaceutical Co., Ltd for EVT 201, a novel potential treatment for insomnia. Pain Alliance with APEIRON Biologics Hamburg, Germany, October 27, 2010 Evotec AG today announced that it has entered into a collaboration with Apeiron Biologics AG, to initially identify small molecule modulators of DREAM, a novel target involved in perception of various pain mechanisms. Evotec and Shionogi Enter Fragment-based Drug Discovery Alliance Hamburg, Germany, October 5, 2010 Evotec AG today announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd., to identify small molecule modulators of various protein-protein interaction targets. Ion Channel Hit Identification Agreement with Almirall Hamburg, Germany, September 23, 2010 Evotec AG today announced that it has entered into a collaboration with Almirall S.A., to identify small molecule modulators of an ion channel target, selected by Almirall, involved in respiratory diseases. Evotec Completes Acquisition of DeveloGen Hamburg, Germany, September 2, 2010 Evotec AG today announced the Closing of the agreement to acquire DeveloGen as announced in detail on 14 July 2010. Strong Milestone Income Leads to Profitable 1st Half Hamburg, Germany, August 12, 2010 Evotec AG today reported financial results and corporate updates for the first half of 2010. Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received Hamburg, Germany, August 4, 2010 Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.5 million to Evotec. Evotec acquires DeveloGen Hamburg, Germany, July 14, 2010 Evotec AG today announced the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company engaged in the discovery of novel therapeutic approaches for the treatment of metabolic and endocrine disorders, for up to € 14m in shares plus performance-related deferred payments. EVT 101 Phase II study started Hamburg, Germany, July 1, 2010 Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101. First Milestone in Oncology Programme with Boehringer Ingelheim Hamburg, Germany, June 17, 2010 Evotec AG today announced that it has achieved a milestone as part of its research alliance with Boehringer Ingelheim and will receive a payment of EUR 2.5 million. Clinical Trial Milestone achieved Hamburg, Germany, May 19, 2010 Evotec AG today announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials. Evotec's Drug Discovery Business Set for Strong Growth Hamburg, Germany, May 12, 2010 Evotec AG today reported financial results and corporate updates for the first quarter of 2010. Integrated Drug Discovery Alliance with Genentech Hamburg, Germany, May 10, 2010 Evotec AG today announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group, to discover novel small molecule therapeutics. Research Grant for H3 Receptor Antagonist Programme Hamburg, Germany, April 27, 2010 Evotec AG today announced that it will receive funding of up to EUR 1.5 million from the German Federal Ministry of Education and Research to advance its H3 receptor antagonist programme into the clinic. 2009 Results: Significant Step towards Sustainability Hamburg, Germany, March 25, 2010 Evotec AG today reported financial results and corporate updates for the year ended 31 December 2009. M&A Advisor Global Healthcare Turnaround Company of the Year Hamburg, Germany, March 23, 2010 Evotec AG has been named the M&A Advisor Healthcare Turnaround Company of the Year for the development and implementation of the 'Evotec 2012 - Action Plan to Focus and Grow'. Agreement with Hypha Discovery to Further Enhance Lead Identification Platform Hamburg, Germany, March 18, 2010 Evotec AG today announced that it has signed an agreement with Hypha Discovery Ltd. Under the terms of the agreement, Evotec will be able to provide its screening clients with access to Hypha’s MycoDiverse™ natural product collection for use as part of its hit and lead identification services. High Throughput Screening Agreement with Active Biotech Hamburg, Germany, March 11, 2010 Evotec AG today announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. Good Progress in Product Development in Treatment-Resistant Depression in its Alliance with Roche Hamburg, Germany, March 10, 2010 Evotec AG today announced two positive aspects that strengthen its integrated product development in treatment-resistant depression in its strategic alliance with Roche. Evotec Extends and Broadens Research Agreement with Cubist Pharmaceuticals Hamburg, Germany, February 25, 2010 Evotec AG today announced that it has extended its research agreement with Cubist Pharmaceuticals, Inc. to the end of 2010. Evotec and Vifor Pharma Sign Major Cooperation Agreement Hamburg, Germany, February 2, 2010 Evotec AG today announced that it has signed an agreement with Vifor Pharma. Evotec and CHDI Foundation, Inc. Extend Collaboration to Fight Huntington's Disease Hamburg, Germany, January 14, 2010 Evotec AG today announced the extension of its collaboration with CHDI Foundation, Inc. through to the end of 2012. 2009 Evotec Achieves Milestone in Medicinal Chemistry Collaboration with Ono Pharmaceutical Co., Ltd. Hamburg, Germany, December 14, 2009 Evotec AG today announced that it has received a milestone payment from Ono Pharmaceutical Co., Ltd. from its research collaboration aimed at identifying novel inhibitors for a protease target. Evotec Wins German Government Research Grant Hamburg, Germany, November 18, 2009 Evotec, a leading provider in the discovery and development of novel small molecule drugs, today announced that it has been granted up to € 2.5 m in research funds from the BMBF, within the Neu2 consortium, to advance research and development activities on the target Serine Racemase for potential use in neuroprotection. Evotec Third Quarter Financial Results Hamburg, Germany, November 12, 2009 Evotec AG today reported results and corporate updates for the third quarter and nine months ended September 30, 2009. Evotec to Voluntarily Delist from NASDAQ Hamburg, Germany, November 10, 2009 Evotec AG a leading provider in the discovery and development of novel small molecule drugs today announced that it plans to voluntarily delist its American Depositary Shares from the NASDAQ stock market and concentrate its share trading on the recently re-entered TecDAX platform. Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration Hamburg, Germany, November 9, 2009 Evotec AG today announced that it has extended the research collaboration with Boehringer Ingelheim for a further 4 years. Evotec Receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim Hamburg, Germany, October 22, 2009 Evotec AG today announced that it has achieved another milestone in its research collaboration with Boehringer Ingelheim. Evotec Signs Agreement with DiscoveRx Corporation to Support High Throughput Screening Services Hamburg, Germany, and Oxford, UK, October 20, 2009 Evotec AG, a leading provider in the discovery and development of novel small molecule drugs and DiscoveRx Corporation, a premier provider of innovative cell based assay solutions, today announced a co-marketing agreement for the screening of GPCR's and other targets. Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical Co., Ltd. Hamburg, Germany, October 15, 2009 Evotec AG today announced that it has extended its current research collaboration with Ono Pharmaceutical Co., Ltd. and initiated a new discovery collaboration. Evotec achieves milestone with Cardioxyl Pharmaceuticals - as compound enters the clinic Hamburg, Germany, October 1, 2009 Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced that the company has achieved an important milestone with Cardioxyl Pharmaceuticals under a collaboration agreement for the compound, CXL-1020, that has successfully moved into clinical testing. Evotec announces Research Agreement with Biogen Idec Hamburg, Germany, September 9, 2009 Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced that it has entered into a research agreement with Biogen Idec, a leading biopharmaceutical company headquartered in Cambridge, Mass., USA. Evotec starts Phase I with EVT 103, an NR2B-selective NMDA receptor antagonist Hamburg, Germany, September 8, 2009 Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today the Phase I clinical study initiation for EVT 103, a small molecule NR2B-selective NMDA receptor antagonist. Evotec completes acquisition of controlling majority stake in Research Support International Private Limited (RSIPL) Hamburg, Germany, August 31, 2009 Evotec AG announced today that the acquisition of the controlling majority stake of Research Support International Private Limited has been successfully completed and that RSIPL is a 70%, majority owned subsidiary of Evotec as of August 31, 2009. Evotec Announces Strong Second Quarter Financial Results Hamburg, Germany, August 7, 2009 Evotec AG today reported results and corporate updates for the second quarter 2009. Evotec Accelerates Growth Strategy of its Discovery Alliance Business with Acquisition of Indian RSIPL Hamburg, Germany, August 6, 2009 Evotec AG and DIL Limited, India, announced today the signing of a definitive agreement to acquire a 70% controlling majority stake of the drug discovery service company RSIPL for EUR 2.8 million in cash, a portion of which includes a potential earn-out. Evotec to Report First Half 2009 Results on August 7, 2009 Hamburg, Germany, July 30, 2009 Evotec AG will report its financial results for the first half of 2009 on Friday, August 7, 2009. Evotec Receives Milestone Payment from Boehringer Ingelheim Hamburg, Germany, July 29, 2009 Evotec AG today announced that a further research milestone, leading to payments to Evotec, has been successfully achieved in its drug discovery collaboration with Boehringer Ingelheim. Evotec Signs High Throughput Screening Collaboration with Alios Biopharma, Inc Hamburg, Germany, July 21, 2009 Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced a collaboration with Alios Biopharma, Inc in the area of high throughput screening. Evotec announces Research Agreement on Fragment- Based Drug Discovery with Cubist Pharmaceuticals Hamburg, Germany, July 14, 2009 Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced that it has entered into a research agreement with Cubist Pharmaceuticals, Inc., a leading acute care biopharmaceutical company located in Lexington, Mass., USA. Evotec-RSIL Ltd extends library synthesis collaboration with Ferrer Grupo Hamburg, Germany, July 7, 2009 Evotec-RSIL Ltd. announced today that Ferrer Grupo, the Spanish pharmaceutical and healthcare company has extended their ongoing collaboration. Evotec Announces the Successful Completion of the First Phase I Study with EVT 401, an Oral P2X7 Receptor Antagonist - Very Good Safety Profile and Confirmed \"On Target Activity\" Hamburg, Germany, June 29, 2009 Evotec AG today announced the successful completion of the first Phase I study with its P2X7 receptor antagonist EVT 401. Evotec Strengthens its Ion Channel Capabilities To Support New Alliances Hamburg, Germany, June 24, 2009 Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced the expansion of its ion channel capabilities with the addition of unique, ion channel focused libraries and additional electrophysiology screening platforms. Evotec Announces First Quarter Results and Corporate Development Update Hamburg, Germany, May 12, 2009 Evotec AG today reported results and corporate development updates for the first quarter ended March 31, 2009. Evotec Acquires Zebrafish Screening Operations of Summit Corporation Hamburg, Germany, May 7, 2009 Evotec AG today announced that the Company will acquire the zebrafish screening operations of Summit Corporation plc, including operations in Abingdon, UK, and Singapore, for £ 0.5 million in cash. Evotec to Re-engineer Drug Discovery and Development Operations Hamburg, Germany, May 5, 2009 Evotec AG announced today that in the context of its Evotec 2012 - Action Plan to Focus and Grow, the Company is re-engineering its drug discovery and development operations to improve efficiency and realize further cost saving potential. Walter Wenninger Nominated for Election as New Supervisory Board Member of Evotec Hamburg, Germany, April 27, 2009 Evotec AG announced today that the Supervisory Board proposes at the next Annual General Meeting to be held on June 4, 2009 the election of Dr Walter Wenninger as new member of the Company's Supervisory Board. Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302 Hamburg, Germany, April 14, 2009 Evotec AG today announced the results of a Phase II proof-of-concept study investigating the potential of EVT 302, a reversible and highly selective inhibitor of monoamine oxidase B, as an aid to smoking cessation. Evotec Restructures and Implements \"Evotec 2012 - Action Plan to Focus and Grow\" Hamburg, March 27, 2009 Evotec AG today announced that it will restructure to focus on core value programs and significantly reduce its operating costs. Evotec Announces Financial Results for 2008 Hamburg, Germany, March 27, 2009 Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today reported financial results for the year ended December 31, 2008. Evotec and Roche to Develop EVT 101 for Treatment-Resistant Depression Hamburg, Germany, March 9, 2009 Evotec AG and Roche announced today that they have entered into an agreement for Phase II clinical development of EVT 101 in patients with treatment-resistant depression. Evotec Appoints Dr. Werner Lanthaler as Chief Executive Officer Hamburg, Germany, March 6, 2009 Evotec AG announced today the appointment of Dr. Werner Lanthaler as Chief Executive Officer of the Company, effective immediately. 2008 Jörn Aldag resigns as CEO of Evotec AG Hamburg, Germany, December 10, 2008 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today that Jörn Aldag will resign from his position as President & Chief Executive Officer of Evotec. The resignation will be effective ... Evotec Announces Three-Year Drug Discovery Collaboration Hamburg, Germany, December 3, 2008 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today announced the start of a research collaboration with Novartis to identify and develop novel small molecule therapeutics. The collaboration ... Evotec Reports Strong Third Quarter 2008 and Improves Full-Year Guidance Hamburg, Germany, November 14, 2008 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today reported results for the third quarter and nine months ended September 30, 2008. Evotec revenues for the first nine months of 2008 were EUR ... Evotec Earns Two Milestone Payments from Boehringer Ingelheim Hamburg, Germany, October 30, 2008 -First compound advanced into Preclinical Development - Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today announced that two further research milestones, leading to total payments to Evotec ... Evotec Reports Phase I Safety Data from Tyramine Interaction Study with EVT 302 Hamburg, Germany, October 27, 2008 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today encouraging results of a Phase I safety study investigating the potential interaction of EVT 302, a reversible and highly selective ... Evotec Announces Phase I Initiation with P2X7 Antagonist Hamburg, Germany, October 9, 2008 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today that Phase I clinical studies for its proprietary, small molecule P2X7 receptor antagonist have been initiated. The P2X7 receptor ... Evotec Participates in the Sale of Direvo Biotech to Bayer Healthcare Hamburg, Germany, September 16, 2008 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today that the Company participates via convertible bonds in the sale of Direvo Biotech AG to Bayer HealthCare AG published this morning. Evotec ... Evotec Reports Start of Phase II Proof-of-Concept Quit Rate Study with EVT 302 and Results of Craving Study Hamburg, Germany, September 11, 2008 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today the start of the Phase II proof-of-concept study, investigating the effect of EVT 302 on the quit rate of patients who want to stop ... Evotec and Boehringer Ingelheim Achieve Milestone in Joint Discovery Collaboration Hamburg, Germany, September 2, 2008 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today announced that a third milestone has been successfully achieved in their collaboration with Boehringer Ingelheim. Under the terms of the drug ... Evotec Reports Results of the First Half of 2008 Hamburg, Germany, August 6, 2008 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today reported results for the first half of 2008. Evotec revenues for the first half of 2008 were EUR 14.5 million, 8% below last year's level ... Evotec Announces Initiation of Phase I Clinical Trial of VR1 Antagonist under Partnership with Pfizer Inc. Hamburg, Germany, August 1, 2008 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today that dose escalation studies for a Phase I clinical trial of a small molecule VR1 (vanilloid receptor 1) antagonist is being progressed by ... Dr Flemming Ornskov Nominated for Election as Chairman of the Supervisory Board of Evotec Hamburg, Germany, July 21, 2008 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today that at its July 9, 2008 meeting the Supervisory Board of Evotec AG decided to propose the election of Dr Flemming Ornskov to the ... Evotec's EVT 101 Well Tolerated in Four Week Higher Repeat Dose Safety Study Hamburg, Germany, July 3, 2008 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today top-line results of a double-blind, 4-week Phase Ib study with EVT 101, an orally active NR2B-subtype selective antagonist of NMDA ... Evotec Reports First Quarter 2008 Results Hamburg, Germany, May 8, 2008 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) reported today results for the first quarter of 2008. Evotec revenues for the first quarter of 2008 were EUR 7.3 million, 16% below last year's ... Evotec Completes Acquisition of Renovis Hamburg, Germany, May 5, 2008 Hamburg, Germany and South San Francisco, CA - Evotec AG (Frankfurt Stock Exchange: EVT) today announced that the merger has been successfully completed and that Renovis, Inc. (traded formerly on NASDAQ: RNVS) is a wholly owned ... Evotec Completes Acquisition of Renovis Hamburg, Germany, May 2, 2008 Hamburg, Germany and South San Francisco, CA - May 2, 2008 - Evotec AG (Frankfurt Stock Exchange: EVT) today announced that the merger has been successfully completed and that Renovis, Inc. (traded formerly on NASDAQ: RNVS) is ... Renovis Stockholders Approve Acquisition by Evotec Hamburg, Germany, May 1, 2008 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT) today announced that the stockholders of Renovis, Inc. (NASDAQ: RNVS) approved the adoption of the merger agreement with Evotec at a special meeting of Renovis ... Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity during the Performance of Cognitive Tasks Hamburg, Germany, March 28, 2008 Single-dose, volunteer fMRI study completed and reported today - Dosing in four week higher repeat dose study completed - Hamburg, Germany | Oxford, UK - Evotec (Frankfurt Stock Exchange: EVT) is pleased to announce the ... Evotec Announces Financial Results for 2007 Hamburg, Germany, March 28, 2008 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) today reported financial results according to IFRS for the year ended December 31, 2007. Financial results for the year were driven by strong ... Ono Enters into a New Fragment-Based Drug Discovery Agreement with Evotec Hamburg, Germany, March 27, 2008 Up to three-year integrated drug discovery support program - Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that the Company and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a new ... Evotec's Registration Statement in Connection with its Proposed Acquisition of Renovis Declared Effective Hamburg, Germany, March 26, 2008 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced today that the U.S. Securities and Exchange Commission (SEC) has declared effective Evotec's ... Spermatech Selects Evotec as Partner for High-Throughput Screening and Lead Discovery Hamburg, Germany, March 12, 2008 Hamburg, Germany | Oxford, UK | Oslo, Norway - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that Spermatech A/S has chosen them as a partner to identify small molecule therapeutics for their pharmaceutical discovery ... Evotec Expands Collaboration with InterMune Hamburg, Germany, March 6, 2008 Fragment-based drug discovery program yields results and leads to expansion of collaboration Hamburg, Germany | Oxford, UK- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that InterMune, Inc., has signed a ... Evotec Starts Phase II in Smoking Cessation with EVT 302 Hamburg, Germany, February 28, 2008 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Ex-change: EVT) today announced the start of its first Phase II study for EVT 302 in smoking cessation, a reversible and highly selective inhibitor of monoamine oxidase B ... Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million Hamburg, Germany, February 14, 2008 - Three-year extension for integrated drug discovery support in the search of novel drug candidates for the treatment of Huntington Disease Hamburg, Germany | Oxford, UK | Los Angeles, CA, USA - Evotec AG (Frankfurt Stock ... Phase I Safety and Tolerability Study with EVT 302 Successfully Completed Hamburg, Germany, January 7, 2008 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) today announced that it has successfully completed a Phase I safety and tolerability study with EVT 302. The preliminary results confirm the good ... Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis Hamburg, Germany, January 7, 2008 Registration statement on Form F-4 filed with the SEC Shares expected to be approved for listing on NASDAQ in H1 2008 Compilation of IFRS financial information resulted in adjustments of Evotec's consolidated financial ... 2007 Evotec Completes Divesture of Chemical Development Hamburg, Germany, December 3, 2007 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) today announced that it has completed the sale of its Chemical Development Business to Aptuit, Inc. for a total consideration of £ 31.5 million ... Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board Hamburg, Germany, November 28, 2007 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) today announced that Dr Mario Polywka and Dr Klaus Maleck have been appointed to the Company's Management Board (Vorstand), as Chief Operating Officer and ... Evotec Reports Third Quarter 2007 Results Hamburg, Germany, November 13, 2007 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) reported today results for the first nine months of 2007. Highlights: Financials in-line with Evotec's full year expectations Compelling results ... Evotec Reports Positive Top-Line Results in Phase II Study with EVT 201 in Elderly Insomniacs with Daytime Sleepiness Hamburg, Germany, October 16, 2007 Statistical significance in primary and key secondary endpoints at both doses Data confirm robust sleep onset and sleep maintenance effects seen in the first Phase II study in the adult population Hamburg, Germany | Oxford, UK - ... Evotec to Acquire Renovis, Seek NASDAQ Listing Hamburg, Germany, September 19, 2007 Merger to Create Emerging Pharmaceutical Company, Broad Pipeline in Neurological and Inflammatory Diseases, Strong Cash Position Conference call to be held at 02.00 pm CET (UK time: 01.00 pm/US: 08.00 am EDT/05.00 am ... Evotec Sells its Chemical Development Business to Aptuit for GBP 31.5m (approx. EUR 46.4m; US$ 63.9m) in Cash Hamburg, Germany, September 11, 2007 Evotec focuses on high-value discovery research and collaborations Chemical Development business to be integrated into global development business of Aptuit Proceeds will allow Evotec to accelerate its CNS pipeline development ... Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia with EVT 201 Hamburg, Germany, September 5, 2007 Very robust findings on the key problems faced by insomniacs, i.e. sleep onset and sleep maintenance Evotec to host a conference call today at 11:00 am CET (10:00 am UK time, 5:00 am EST, 7:00 pm AEST) directly from the ... European Centre for Modern Drug Discovery Established in Hamburg Hamburg, Germany, September 3, 2007 Hamburg is on its way to becoming a leading hub of Europe's academic drug discovery, with the northern German city's town hall today announcing the foundation of European ScreeningPort GmbH, a company that will run a ... Evotec Reports First Half 2007 Results and Business Update Hamburg, Germany, August 14, 2007 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) reported today results for the first half of 2007. Highlights: Revenues in-line with Evotec's full year expectations First proof-of-concept ... Evotec Announces the Expansion of its GMP Sterile Pharmaceutical Manufacturing Facility Hamburg, Germany, July 17, 2007 Hamburg, Germany | Oxford, UK | Glasgow, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today the expansion of its sterile pharmaceutical manufacturing facility in Glasgow, Scotland. The Company has doubled its capacity ... Evotec and Research Support International Limited Announce the Formation of Evotec-RSIL Ltd, a Joint Venture for the Design, Synthesis, Management and Commercialisation of Compound Libraries Hamburg, Germany, July 11, 2007 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) and Research Support International Limited (RSIL), a subsidiary of DIL Ltd, announced today the formation of a joint venture in India, Evotec-RSIL Ltd, to ... Evotec Enhances its Fragment-Based Drug Discovery Business by the Addition of NMR Screening Assets from Combinature Hamburg, Germany, June 13, 2007 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that it has enhanced its Fragment-Based Drug Discovery business through the acquisition of selected assets from Combinature Biopharm. ... Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201 Hamburg, Germany, June 4, 2007 Both co-primary endpoints, Wake After Sleep Onset and Total Sleep Time, and key secondary Endpoints, including Latency to Persistent Sleep, were met at both doses Evotec to host a conference call at 4pm CET (3pm UK time, 10am ... Evotec to Launch its First Innovation Centre for Fragment Based Drug Discovery Hamburg, Germany, May 21, 2007 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today the launch of its Innovation Centre for Fragment Based Drug Discovery ('FBDD'). FBDD offers an alternative approach for identifying novel, ... Evotec Reports Q1 2007 Results and Pipeline Progress Hamburg, Germany, May 10, 2007 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) reported a solid set of quarterly numbers today, inline with guidance for 2007. Evotec revenues for the first quarter 2007 were EUR 15.1 million and ... Panacos Extends Medicinal Chemistry Contract with Evotec into Fourth Year and Expands into Development Chemistry Hamburg, Germany, May 10, 2007 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that Panacos Pharmaceuticals, Inc. (NASDAQ: PANC) has extended its ongoing discovery collaboration with Evotec into its fourth year. ... Evotec Announces Encouraging FY 2006 Financial Results , March 29, 2007 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) today reported financial results for the year ended 31 December 2006. Total Group revenues increased by 6% to 84.7m and net income improved to -32.5m ... Evotec Initiates its First Phase I Clinical Study with EVT 302 Hamburg, Germany, March 22, 2007 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today the initiation of its first Phase I study with EVT 302. This open-label study is designed to access the occupancy of the monoamine oxidase ... Evotec and Boehringer Ingelheim Enter into Target Discovery Collaboration in Alzheimer's Disease Hamburg, Germany, March 19, 2007 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) today announced a multi-year collaboration with Boehringer Ingelheim to jointly identify novel targets as potential points of intervention in the treatment ... Evotec and Interprotein Sign Collaboration Agreement to Develop Interleukin 6 Inhibitors to Treat Inflammatory Diseases Hamburg, Germany, February 28, 2007 Hamburg, Germany | Oxford, UK | Amagasaki-City, Japan - Evotec AG (Frankfurt Stock Exchange: EVT) and Interprotein Corporation (previously IntercytoNanoScience Co., Ltd.) proudly announce today that they have signed a ... Evotec Wins Key Contracts with Solvay Pharmaceuticals: Fragment-Based Drug Discovery and a Third Extension of the Library Synthesis and Medicinal Chemistry Collaboration Hamburg, Germany, January 22, 2007 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announced the signing of two contracts with Solvay Pharmaceuticals, a member of the Solvay group specialising in global pharmaceutical R&D, ... 2006 PerkinElmer to Acquire Evotec Technologies Hamburg, Germany, December 1, 2006 Focuses Evotec on core business drug discovery and development Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) yesterday evening announced that PerkinElmer Inc. (NYSE: PKI) signed a ... Evotec Initiates Second Phase II Clinical Trial with Insomnia Drug EVT 201 Hamburg, Germany, November 17, 2006 Study in elderly patients with primary insomnia and daytime sleepiness Hamburg, Germany | Oxford, England - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announced today the initiation of a second Phase II study ... Evotec Reports Strong Q3 Growth Hamburg, Germany, November 9, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (ISIN: DE000 5664809, EVT) today reported strong growth in revenues and profits for the third quarter 2006. Group revenues of the Hamburg-based drug discovery and development company ... Evotec Technologies Installs plate::explorer(TM) and Opera(TM) for High Throughput Screening at the Genome Research Institute Hamburg, Germany, October 20, 2006 Hamburg, Germany and Cincinnati, Ohio - Evotec Technologies GmbH, a supplier of innovative tools and technologies for life sciences and pharmaceutical drug discovery, the Genome Research Institute (GRI) at the University of ... Daiichi Pharmaceutical Selects Evotec as Partner for Medicinal Chemistry and Compound Profiling Hamburg, Germany, October 16, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that it has signed a research collaboration agreement with Daiichi Pharmaceutical Co., Ltd. (a wholly owned subsidiary of ... Evotec Achieves Certificate of GMP Compliance from MHRA Hamburg, Germany, September 28, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced it has received a Certificate of GMP Compliance from the Medicines and Healthcare Products Regulatory Agency (MHRA). This ... Evotec Initiates Phase II Clinical Trial with EVT 201 for the Treatment of Insomnia , September 21, 2006 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") announced today the initiation of a Phase II clinical trial with EVT 201 for the treatment of insomnia under a US IND. This US, multi-centre, ... Evotec Appoints David Brister Chief Business Officer Hamburg, Germany, September 19, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announced today that David Brister has been appointed Chief Business Officer and a member of the Company's Executive Committee. In this newly ... Evotec Discontinues EVT 301 Development Programme Hamburg, Germany, September 13, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today reported that during the one month safety and tolerability study with EVT 301 in young and elderly volunteers, several cases of ... Evotec Reaches Second Milestone and Receives Success Payment in Alzheimer's Disease Collaboration with Takeda Hamburg, Germany, August 16, 2006 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") announced today that the second milestone has been achieved in its four-year drug discovery collaboration with Takeda Pharmaceutical Company ... Evotec Reports Encouraging Results for the First Half Year and Confirms Guidance Hamburg, Germany, August 11, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (ISIN: DE000 5664809, EVT) today reported financial results for the second quarter 2006. Revenues for the second quarter 2006 increased by 2% to EUR 18.8 million (Q2 2005: EUR 18.4 ... CHDI Selects Evotec as Strategic Drug Discovery Partner in the Search for Huntington Disease Treatments Hamburg, Germany, August 10, 2006 -Four contracts signed since March 2006 covering most of Evotec's drug discovery capability - Hamburg, Germany | Oxford, UK | Los Angeles, CA, USA - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that ... Evotec Successfully Completes Phase I for Potential Alzheimer's Disease and Neuropathic Pain Treatment, EVT 101 Hamburg, Germany, August 8, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") today announced the successful completion of Phase I with EVT 101, an NR2B subtype-specific NMDA receptor antagonist for the treatment ... Evotec Sells Single Molecule Detection Technology & IP Portfolio to Olympus Hamburg, Germany, July 24, 2006 Evotec Sells Single Molecule Detection Technology & IP Portfolio to Olympus DAC Selects Evotec as Strategic Partner for a Drug Discovery Collaboration on the HSP90 Cancer Target Hamburg, Germany, July 18, 2006 - DAC in-licences compound intellectual property identified using Evotec's proprietary fragment screening platform - Hamburg, Germany | Oxford, UK | Milan, Italy - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today ... Evotec and Roche Form Global Alliance to Jointly Discover Novel Drugs Hamburg, Germany, June 21, 2006 Hamburg, Germany | Oxford, UK | Basel, Switzerland - Roche and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30; Evotec) today announced that they have formed an alliance to jointly discover and develop compounds against a ... Evotec Announces Positive Phase I/II Clinical Trial Results with Insomnia Treatment EVT 201 Hamburg, Germany, June 8, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announced today top-line results of the proof-of-principle study for its GABA-A modulator EVT 201, for the treatment of insomnia. The Phase I/II ... Evotec Announces Q1 2006 Financial Results Hamburg, Germany, May 11, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the first quarter 2006. Q1 Highlights: Rapidly progressing CNS pipeline:EVT 301, a Phase I compound ... Sankyo Selected Evotec as Assay Development and Screening Partner Hamburg, Germany, April 27, 2006 Hamburg, Germany | Oxford, UK | Tokyo, Japan - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that Sankyo (a wholly owned subsidiary of DAIICHI SANKYO COMPANY, LIMITED) has chosen Evotec as a partner to ... Evotec Signs Two Significant Contracts with Roche Hamburg, Germany, April 25, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that it signed two significant service contracts with Roche. These contracts build on the companies' long-standing relationship ... University of Cincinnati and Cincinnati Children's Hospital Medical Center Partner with Evotec to Enhance Drug Discovery Hamburg, Germany, April 4, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) will partner with the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center (Cincinnati Children's) to enhance the ... Evotec Announces Full Year 2005 Financial Results Hamburg, Germany, March 28, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the year ended 31 December 2005. 2005 Highlights: Rapidly progressing CNS pipeline: First ... Evotec and Boehringer Ingelheim Achieve Second Milestone in Joint Discovery Collaboration Hamburg, Germany, March 10, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that the second milestone in its research collaboration with Boehringer Ingelheim has been successfully achieved. Under the ... Evotec and Apeiron Biologics to Discover Novel Pain Therapeutics Hamburg, Germany, February 14, 2006 Hamburg, Germany | Oxford, UK | Vienna, Austria - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) and Apeiron Biologics GmbH today announced that they have entered into a discovery collaboration to develop small molecules ... Evotec Successfully Completes Single Ascending Dose Component of Phase I Trial with EVT 101 for Alzheimer's Disease Hamburg, Germany, February 3, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") today announced the successful completion of the single ascending dose component of the Phase I clinical study with EVT 101, a ... Evotec and Boehringer Ingelheim Significantly Expand and Extend their Joint Drug Discovery Collaboration Hamburg, Germany, January 17, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") today announced that effective from 1 January 2006 Evotec and Boehringer Ingelheim GmbH ("Boehringer") will significantly expand their ... Evotec Licenses Two Phase I Compounds with Disease Modifying Potential in Alzheimer's Disease Hamburg, Germany, January 9, 2006 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that it has signed an exclusive worldwide licensing agreement with Roche for two compounds in phase I clinical development for ... 2005 Evotec Reaches First Milestone and Receives Success Payment in Alzheimer's Disease Collaboration with Takeda Hamburg, Germany, December 6, 2005 Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") announced today that the first milestone has been achieved in its four-year drug discovery collaboration with Takeda Pharmaceutical Company Limited ... 3i has reduced its interest in Evotec to 4.1% Hamburg, Germany, November 29, 2005 - Remaining interest to be held for the long-term -Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that the venture capital company 3i has, in the course of the current ... Evotec Announces Initiation of Phase I Clinic Trial with EVT 101 Hamburg, Germany, November 14, 2005 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced initiation of a Phase I study with EVT 101, its NR2B subtype selective NMDA receptor antagonist for the potential ... Third Quarter 2005: Third consecutive quarter of strong services performance and first compound in Phase I clinical trials Hamburg, Germany, November 9, 2005 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the third quarter and the nine months to the end of September 2005. Highlights: Development of a ... Boehringer Ingelheim Extends Scope of Collaboration with Evotec into Screening Services - New agreements signed with Boehringer Ingelheim Germany and Canada Hamburg, Germany, November 3, 2005 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that Boehringer Ingelheim (Boehringer) has extended the scope of its collaboration with Evotec. In addition to the substantial ... Evotec Reports Positive Results of Repositioning Clinical Trial on CNS Compound Hamburg, Germany, October 20, 2005 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announces today that the repositioning study of its CNS-active compound (see press release of 18 March 2005) has been completed with positive ... ProPharma Integrated into Evotec Services Division Hamburg, Germany, September 8, 2005 Hamburg, Germany | Oxford, UK | Glasgow, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that ProPharma Limited, its formulation subsidiary based in Glasgow, Scotland, will do business under the Evotec ... Second Quarter 2005: Evotec Progressing as Planned Hamburg, Germany, August 11, 2005 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the second quarter and the six months to the end of June 2005. Highlights: Development of a ... Procter & Gamble Selects Evotec as Provider of Pharmaceutical Discovery and Chemical Development Services Hamburg, Germany, July 25, 2005 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) and Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company (NYSE - PG), today announced that ... Evotec Enters into Long-Term Focused Library Agreement with Almirall - Value Exceeding EUR 2.5 m over the Two-Year Contract Period Hamburg, Germany, July 21, 2005 Hamburg, Germany | Oxford, UK | Barcelona, Spain - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) and Almirall Prodesfarma S.A., the leading Spanish multinational company, today announced that they have entered into a ... Evotec Names Dr Tim Tasker Executive Vice President Clinical Development and Member of the Executive Committee Hamburg, Germany, July 5, 2005 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced the appointment of Dr Tim Tasker as Executive Vice President Clinical Development and a member of its Executive Committee. He ... Evotec Raised EUR 28.4 Million in Capital Increase Hamburg, Germany, June 24, 2005 Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announces today that its capital increase of up to 10,457,402 new Evotec shares against contribution in cash has been fully subscripted. The ... Evotec OAI Announces AGM Approval of Capital Increase and New Supervisory Board Structure Hamburg, Germany, June 7, 2005 Hamburg, Germany, and Oxford, UK, 07.06.2005Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announces that at the annual shareholder meeting today the Company's shareholders approved the following agenda items which are ... Evotec OAI Achieves First Milestone in Partnership with Boehringer Ingelheim Hamburg, Germany, June 7, 2005 Hamburg, Germany | Oxford, UK | Ingelheim, Germany - In less than one year after the start of the three-year research collaboration between Boehringer Ingelheim and Evotec OAI (Frankfurt Stock Exchange: EVT, TecDAX 30) on ... First Quarter 2005: Full-Year Guidance Confirmed Following Strong Q1 2005 Hamburg, Germany, May 10, 2005 Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the first quarter 2005. Financial highlights: * Revenues for the first quarter increased ... Evotec OAI Proposes Changes to its Supervisory Board to Support the Implementation of its Strategy of Proprietary Drug Development Hamburg, Germany, May 6, 2005 Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that it intends to restructure its Supervisory Board following the acquisition of Evotec Neurosciences (ENS) in March 2005. ... Evotec OAI Extends Global Medicinal Chemistry Agreement with Roche Hamburg, Germany, April 13, 2005 Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leader in integrated high-value-added drug discovery and development, today announced that they have extended their global discovery ... Evotec OAI AG Report Financial Results 2004 and Guidance for 2005: Strong Q4 and Solid Outlook Hamburg, Germany, March 22, 2005 Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the year ended 31 December 2004. All figures reported today are in-line with the Company's guidance ... Evotec Acquires ENS and Secures €47m in Cash to Develop CNS Pipeline Hamburg, Germany, March 6, 2005 Download PDFEvotec increases focus on proprietary drug discovery and development and emphasis on cash generation in contract researchHamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT) ("Evotec" or "the ... Evotec OAI to Provide Process Validation for AnorMED Inc. Phase III Compound, AMD 3100 Hamburg, Germany, February 16, 2005 Hamburg, Germany | Oxford, UK | Vancouver, Canada - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading provider of integrated, high-value-added drug discovery and development solutions, today announced that ... Evotec OAI's Preliminary Results 2004: Strong Q4 Performance Hamburg, Germany, February 3, 2005 Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX30) today reported preliminary financial results for the fourth quarter and the full year 2004. Evotec OAI exceeds its 2003 revenue and ... Evotec OAI Appoints Mary Tanner to its Supervisory Board: New Board Member brings significant life science and investment banking expertise Hamburg, Germany, January 19, 2005 Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced the appointment of Mary C. Tanner to the Company's Supervisory Board with immediate effect. Mary Tanner brings 22 ... 2004 Evotec Technologies provides EVOscreen® and Opera to Korea Hamburg, Germany, December 21, 2004 Hamburg, Germany - Evotec Technologies GmbH (Evotec), a supplier of innovative tools and technologies for life sciences and pharmaceutical drug discovery, today announced the successful set-up of Evotec's ultra high throughput ... Third Quarter 2004: On Track to Reach Updated Financial Targets Hamburg, Germany, November 11, 2004 Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the third quarter and the nine months to the end of September 2004. Financial highlights: ... Evotec OAI Updates Guidance for 2004 and Provides Preliminary Third Quarter Revenues Hamburg, Germany, October 20, 2004 Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announces updates on 2004 financial guidance and provides preliminary third quarter revenues. For the first nine months of 2004 ... ALTANA Pharma Selects Evotec OAI as Partner for a Kinase Lead Identification Programme Hamburg, Germany, October 6, 2004 Evotec Technologies and QIAGEN Demonstrate Significant Benefits of Combining High-Content Cellular Imaging Systems with RNAi Applications Hamburg, Germany, September 13, 2004 Hamburg, Germany and Venlo, The Netherlands - Evotec Technologies GmbH and QIAGEN N.V. (Nasdaq: QGENF; Deutsche Börse: QIA, Prime Standard) today announced that they have signed an agreement to promote the benefits of ... Evotec Neurosciences and Evotec OAI Enter into Joint Drug Discovery Collaboration with Boehringer Ingelheim to Identify GPCR Modulator-based New Medicines Hamburg, Germany, September 8, 2004 Hamburg, Germany | Oxford, UK | Ingelheim, Germany - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) and Evotec Neurosciences GmbH today announced a three year research collaboration with Boehringer Ingelheim. The ... Bernard Questier Leaves Management Board of Evotec OAI Hamburg, Germany, August 26, 2004 Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that by mutual agreement Bernard Questier will depart from his position as Chief Business Officer. He will pursue new ... Seikagaku Selects Evotec OAI as Assay Development and Screening Partner Hamburg, Germany, August 11, 2004 Hamburg, Germany | Oxford, UK | Tokyo, Japan - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and ... Second Quarter 2004: Revenues Rebound From Q1 - Good Progress in Difficult Market Environment Hamburg, Germany, August 11, 2004 Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced financial results for the second quarter and the six months to the end of June 2004. Financial highlights: ... Evotec OAI to Apply New Rational Drug Design Platform, EVOrationale(TM), to High Priority Research Programme from ActivBiotics Hamburg, Germany, July 29, 2004 Hamburg, Germany | Oxford, UK | Lexington, MA, USA - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and ... Morphochem Selects Evotec OAI as a Partner for the Chemical and Pharmaceutical Development of its Dual Action Antibiotic Oxaquin Hamburg, Germany, July 21, 2004 Hamburg, Germany | Oxford, UK | München, Germany - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated, high-value-added drug discovery and development solutions, today announced that ... Biogen Idec Selects Evotec OAI as a Service Provider for Process Research & Development Hamburg, Germany, July 19, 2004 Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated, high-value-added drug discovery and development solutions, today announced that Biogen Idec (Nasdaq: ... Evotec OAI Announces Preliminary Q2 Sales Significantly Improved from Q1 2004 - On Track to Meet Full-Year Guidance Hamburg, Germany, July 12, 2004 Hamburg, Germany | Oxford, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today reported preliminary sales figures for the second quarter ended 30 June 2004. The Company achieved second quarter revenues of ... Evotec OAI Undergoes Successful FDA Inspection Hamburg, Germany, June 18, 2004 Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated, high-value-added drug discovery and development solutions, today announced a recent successful ... Neuronova AG Selects Evotec OAI as their Assay Development and Screening Partner Hamburg, Germany, June 14, 2004 Hamburg, Germany | Oxfordshire, UK | Munich, Germany - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and ... Evotec OAI Enters into Discovery Agreement with Nuvios Hamburg, Germany, May 19, 2004 Hamburg, Germany | Oxfordshire, UK | Cambridge, MA, USA - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated, high-value-added drug discovery and development services, today announced a ... Guilford Pharmaceuticals Selects Evotec OAI as their Assay Development and Screening Partner Hamburg, Germany, May 13, 2004 Hamburg, Germany | Oxfordshire, UK | Baltimore, MD, USA - Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the ... Evotec OAI and Roche enter into Strategic Global Discovery Chemistry Agreement Hamburg, Germany, May 12, 2004 Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology ... First Quarter 2004: Delivering on Forecast and Strategy Hamburg, Germany, May 12, 2004 Hamburg, Germany | Oxfordshire, UK - Evotec OAI (Deutsche Börse: EVT, TecDAX 30) today announced financial results for the first quarter 2004. Financial highlights: - Q1 revenues amounted to EUR 14.4 million ... Evotec OAI Expands ADMET Platform, EVOprofile Hamburg, Germany, May 7, 2004 Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology ... Evotec OAI to Expand Agreement with Oxford Bioscience Partners through Integration of its New Rational Drug Design Platform, EVOrational Hamburg, Germany, April 26, 2004 Hamburg, Germany | Oxfordshire, UK | Boston, USA - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and ... Evotec OAI Enters into Integrated Virtual Screening and Medicinal Chemistry Agreement with Fujisawa Hamburg, Germany, April 13, 2004 Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology ... Evotec Neurosciences Completes € 25 Million Series A Financing Hamburg, Germany, April 2, 2004 Hamburg, Germany - Evotec Neurosciences (ENS), a subsidiary of Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), today announced that it has secured a € 25 million first round of venture capital financing. The ... Evotec OAI and Panacos Enter into Medicinal Chemistry Agreement to Design and Optimise Novel Anti-HIV Compounds Hamburg, Germany, March 25, 2004 Hamburg, Germany | Oxfordshire, UK | Gaithersburg, MD, USA - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical ... Evotec Neurosciences to licence NMDA receptor NR2B subunit selective antagonists from Roche Hamburg, Germany, March 25, 2004 Hamburg, Germany - Evotec Neurosciences GmbH (ENS), a subsidiary of Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), today announced that it has acquired from Roche an exclusive worldwide license to develop and market an ... Evotec OAI AG - Financial Results 2003: Strategy delivers strong revenue growth and positive EBITDA Hamburg, Germany, March 25, 2004 Hamburg, Germany | Oxfordshire, UK - Evotec OAI (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries, ... Evotec OAI Announces Re-organisation of it's Executive Management to Reflect the Growing Strengths of its Core Businesses Hamburg, Germany, February 17, 2004 Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG, (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development to the pharmaceutical and biotechnology industries, today ... Evotec OAI's Preliminary Results 2003 Show Strong Sales Growth and Robust EBITDA Profitability Hamburg, Germany, February 16, 2004 Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology ... Evotec OAI and Toray Sign Integrated Medicinal Chemistry, Virtual Screening and Compound Profiling Agreement Hamburg, Germany, February 11, 2004 Hamburg, Germany | Oxfordshire, UK | Tokyo, Japan - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, and Toray ... Evotec OAI and Rib-X Pharmaceuticals Enter Into Medicinal Chemistry Collaboration Hamburg, Germany, January 14, 2004 Hamburg, Germany | Oxfordshire, UK | New Haven, CT, USA - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, and Rib-X ... 2003 Third Quarter 2003: Evotec OAI Reports 9-month Revenues up 20%, Positive EBITDA Sustained Hamburg, Germany, November 12, 2003 "This has been another excellent quarter for Evotec OAI. Despite continuing challenging market conditions and adverse currency effects, revenues continued to rise strongly and we remain firmly on track to post our first year of ... Evotec OAI and Roche Sign Medicinal Chemistry Collaboration in Oncology Hamburg, Germany, October 22, 2003 Roche and Evotec OAI have worked together on the production of chemical libraries since 2001, with Evotec OAI supplying chemical compound libraries to Roche for use in drug discovery screening programmes. This agreement expands ... Evotec OAI and Biofrontera to Offer Natural Compounds for Drug Discovery Services Hamburg, Germany, October 14, 2003 Biofrontera's huge, largely unexploited pool of natural compounds constitutes a rich source of potential drug candidates. About 140,000 subfractions, containing over 2 million compounds, are immediately available for screening ... Evotec OAI and DeveloGen Announce a Strategic Drug Discovery and Development Alliance for Metabolic Diseases Hamburg, Germany, September 10, 2003 This collaboration is a strategic first for both companies, where the partners share risks and rewards equally. The partnership creates an integrated venture combining DeveloGen's pipeline of over 200 primary targets and 30 ... Second Quarter 2003: Evotec OAI Reports Positive EBITDA in First Half Hamburg, Germany, August 12, 2003 Financial highlights:Revenues increased to EUR 34.8 m (+5%). At constant exchange rates, sales rose by 16% EBITDA positive in first half; on track for full-year sales growth of 10-15% and positive EBITDA in 2003 Operating loss ... Evotec OAI Appoints Bernard Questier Chief Business Officer Hamburg, Germany, August 6, 2003 Bernard Questier, 49, will join Evotec OAI with effect from 6 October 2003. Being based in the Company's headquarter in Hamburg, Germany, he will lead Evotec OAI's business development functions as a member of the Management ... Evotec Neurosciences and Takeda enter into drug discovery alliance in Alzheimer's disease Hamburg, Germany, August 1, 2003 ENS will grant Takeda access to its proprietary database of Alzheimer's disease-related targets, and further validate selected target candidates for downstream drug discovery programs. Takeda will make payments to Evotec ... Evotec OAI Signs Medicinal Chemistry Agreement with Axxima Pharmaceuticals Hamburg, Germany, June 25, 2003 Under the terms of the drug discovery contract Evotec OAI will apply its integrated medicinal chemistry platform to optimise initial screening hits already identified by Axxima and rapidly progress them towards novel clinical ... Artesian Therapeutics Selects Evotec OAI as Drug Discovery Partner Hamburg, Germany, May 15, 2003 Hamburg, Germany | Abingdon, UK | Gaithersburg, USA - Evotec OAI (Deutsche Börse: EVT, TecDAX 30), a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, and ... First Quarter 2003: Evotec OAI Reports Good Start to 2003 Hamburg, Germany, May 8, 2003 Financial highlights: Revenues increased to EUR 17.8 m (+5%) although adverse currency effects had an impact on business in Q1. At constant exchange rates growth would have been +15%. Reduced SG&A and R&D expenses led ... Evotec OAI and Novartis Pharma AG Sign Lead Discovery Collaboration Hamburg, Germany, April 10, 2003 Joern Aldag, President and Chief Executive Officer of Evotec OAI, commented: "Following a successful collaboration in the development of our EVOscreen® uHTS system, Novartis has chosen Evotec OAI to support their lead discovery efforts. We are delighted that one of the world's leading R&D organisations has chosen our expertise in drug discovery and our technology platform in this critical area of research." Evotec OAI AG - Financial Results 2002, Sustained Growth in Challenging Markets Hamburg, Germany, March 25, 2003 Financial Highlights: Group Revenues EUR 70.0 million, up 11% Discovery and Development Services revenues EUR 58.6 million, up 13% EBITDA EUR (2.2) million, exceeding company October 2002 guidance (EUR (3) to (6) million); ... British Biotech to transfer research operations to Evotec OAI Hamburg, Germany, March 21, 2003 The principal terms of the agreement are: 17 research scientists to transfer from British Biotech to Evotec OAI; Evotec OAI to provide medicinal chemistry and biology services under contract to support British Biotech's ... Psychiatric Genomics Selects Evotec OAI as Their Strategic Chemistry Partner for Drug Discovery and Development Hamburg, Germany, January 30, 2003 Download PDF Hamburg, Germany | Oxford, UK | Gaithersburg, Maryland, USA - Evotec OAI AG (Deutsche Börse: EVT, Prime Standard), a partner for integrated high-value-added drug discovery services to the pharmaceutical and ... Evotec OAI's Preliminary Results 2002: Q4 Results Exceeding Expectations Hamburg, Germany, January 30, 2003 Hamburg, Germany | Abingdon, UK - Evotec OAI AG (Deutsche Börse: EVT, Prime Standard), a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, today reported ... Evotec OAI to Support Dynogen Pharmaceuticals in the Discovery and Development of Novel Pharmaceuticals Hamburg, Germany, January 30, 2003 Download PDF"Dynogen's near term strategic approach is to acquire neurological compounds which have been developed for pain, depression, anxiety or other indications and develop them for GU and GI disorders. Longer term, we plan ... Euroscreen and Evotec OAI Partner GPCR Expertise - Companies Provide Comprehensive GPCR Screening, Product and Research Services Hamburg, Germany, January 20, 2003 Hamburg, Germany | Abingdon, UK | Brussels, Belgium - Evotec OAI AG (Deutsche Börse: EVT, Prime Standard) and Euroscreen S.A. today announced they have exchanged know how and expertise to enhance their respective strengths ... Evotec OAI Achieves Milestone with Clinical Advancement of Vertex Pharmaceuticals Compound Hamburg, Germany, January 16, 2003 As part of an agreement that began in 1998, Vertex has utilised a broad range of chemistries Evotec OAI has to offer and Evotec OAI has provided compounds and compound arrays for pharmaceutical screening and lead optimisation. ... Evotec OAI Announces Drug Discovery Agreement with KeyNeurotek and the Institute of Medical Technology Magdeburg (IMTM) Hamburg, Germany, January 14, 2003 Under the terms of the collaboration, Evotec OAI will assist KeyNeurotek and IMTM to develop new lead structures with respect to two of their partners' proprietary targets. This program is partly supported by the ... Evotec OAI and Oxagen Initiate Drug Discovery Alliance Hamburg, Germany, January 8, 2003 In the search for new drugs Evotec OAI will apply its fully integrated drug discovery process know-how to express the target of interest, develop Ca2+ flux assays, screen the target against its corporate library of drug-like ... 2002 Achillion Selects Evotec OAI as Preferred Partner for Clinical Compound Manufacturing Hamburg, Germany, December 11, 2002 Hamburg, Germany | Abingdon, UK - Evotec OAI AG (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, today announced that Achillion Pharmaceuticals, Inc. ... Evotec OAI Names Ian Hunneyball President of Discovery Services and Member of the Management Board Hamburg, Germany, December 9, 2002 Evotec OAI Names Ian Hunneyball President of Discovery Services and Member of the Management Board Evotec OAI Extends Medicinal Chemistry Agreement with Avidex Hamburg, Germany, December 6, 2002 Hamburg, Germany | Abingdon, UK - Evotec OAI AG (NM: EVT), a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, announced today that it has signed an extension to ... Evotec OAI to Collaborate with Prolysis in the Development of New Antibiotics Hamburg, Germany, December 4, 2002 Hamburg, Germany | Oxford, UK - Evotec OAI AG (NM: EVT), a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, and Prolysis Ltd. (Oxford, UK), a biotechnology ... Evotec OAI: Direvo Raises EUR 10.5 Million in Series B Financing Hamburg, Germany, November 26, 2002 Hamburg, Germany | Abingdon, UK - Evotec OAI AG (NM: EVT), a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, announced today that Direvo Biotech AG has raised ... Evotec OAI Extends Discovery Agreement with Solvay Pharmaceuticals Hamburg, Germany, November 25, 2002 Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, announced today a one-year ... Elixir Pharmaceuticals to Access Broad Chemical and Biological Drug Discovery and Development Services in Agreement with Evotec OAI Hamburg, Germany, November 21, 2002 Deal Marks First Agreement under Innovative Alliance between Evotec OAI and Oxford Bioscience Partners Hamburg, Germany | Abingdon, UK | Cambridge, Mass., USA - Evotec OAI AG (NM: EVT), a partner for integrated ... Third Quarter 2002: Evotec OAI Reports Solid Performance in Difficult Market Environment Hamburg, Germany, November 14, 2002 Download PDF 9 months sales increase of 20% to EUR 47.5m, in line with company guidance Growth in Q3 of 8% lead to a more cautious outlook on sales and profit targets EBITDA slightly below last year (EUR ... Evotec OAI Enters into Innovative Drug Discovery and Development Agreement with Venture Capital Firm Oxford Bioscience Partners Hamburg, Germany, November 14, 2002 Download PDFHamburg, Germany | Abingdon, UK | Boston, USA - Evotec OAI AG, Hamburg, Germany (NM: EVT), a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, and ... Evotec Technologies: EVOscreen® Mark III Successfully Passed Site Acceptance Testing at Novartis Hamburg, Germany, November 14, 2002 Hamburg, Germany - Evotec Technologies GmbH, a subsidiary of Evotec OAI AG (Neuer Markt: EVT) providing innovative technologies for life sciences, announced today the implementation of the second ultra-high-throughput screening ... Evotec OAI Announces Medicinal Chemistry Agreement with British Biotech Hamburg, Germany, November 7, 2002 Download PDFHamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, announced today that ... Evotec OAI Successfully Completes Assay Development Programme with ALTANA Pharma AG Hamburg, Germany, November 4, 2002 Download PDF Second collaboration milestone achieved Evotec OAI's cell analyzer "Opera" to be integrated into ALTANA Pharma's drug discovery platform Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer ... Evotec OAI Expands Long-Term Screening Technology Alliance with Pfizer Hamburg, Germany, October 31, 2002 Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, announced today that it has ... Evotec OAI Announces Update on Annual Guidance Hamburg, Germany, October 23, 2002 Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT) announces third quarter revenues and an update on the company's forecast for its 2002 financial performance. "Based on our excellent ... Evotec Technologies Launches High-Throughput Cell Analyser 'Opera' Hamburg, Germany, October 10, 2002 Revolution in high-content analysis of cellular events in assay development and screening Hamburg, Germany - Evotec Technologies GmbH, Hamburg, Germany, a wholly-owned subsidiary of Evotec OAI AG (Neuer Markt: EVT) providing ... Evotec OAI Grants Licence to Roche Diagnostics Hamburg, Germany, August 22, 2002 Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, today announced that it granted a ... Second Quarter 2002: Evotec OAI Meeting its Growth Targets Hamburg, Germany, August 20, 2002 Sales increase of 26% to EUR 33.2 million, in line with company guidance Net loss reduced by 82% to EUR (13.7) million EBITDA improved by 28% Cash burn significantly reduced year-on-year Strong order book ... Evotec OAI Announces Key Management Appointments To Position For the Next Phase Of Growth Hamburg, Germany, June 25, 2002 Dr John Kemp joins from Roche to become Chief Executive Officer of Evotec Neurosciences GmbH with responsibility for Discovery Programmes (Central Nervous System) New post of President of Discovery Services, the Company's ... Infinity Pharmaceuticals Selects Evotec OAI as Their Assay Development and Screening Partner Hamburg, Germany, June 13, 2002 Hamburg, Germany | Abingdon, UK | Boston, USA - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, announced today the ... Evotec OAI and U3 Pharma Sign Screening and Drug Discovery Collaboration Hamburg, Germany, June 6, 2002 Hamburg and Martinsried, Germany | Abingdon, UK - Evotec OAI AG (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, announced today the signing of a ... Evotec OAI and Taisho Pharmaceutical Co., Ltd. Start Drug Discovery Collaboration Hamburg, Germany, May 22, 2002 Hamburg, Germany | Abingdon, UK | Tokyo, Japan - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high value added drug discovery services, announced today that it has entered into a drug discovery ... Evotec OAI AG - First Quarter 2002: Overachieved revenue goal for Q1 and strong order book for 2002 Hamburg, Germany, May 15, 2002 Sales increase of 50% to EUR 16.9 million 42% growth in drug discovery services Net loss reduced by 86% to EUR (5.7) million EBITDA of EUR (0.7) million close to break-even Cash burn significantly reduced to EUR ... Evotec OAI Signs Contract Extension with Vertex Pharmaceuticals Hamburg, Germany, May 15, 2002 Download PDFHamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high value added drug discovery services, announced today that it will continue to provide drug discovery ... Evotec OAI and Novartis intensify collaboration Hamburg, Germany, May 8, 2002 Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high value added drug discovery services, announced today that its long-term partner Novartis will acquire additional ... Roche extends Discovery Chemistry Agreement with Evotec OAI Hamburg, Germany, April 29, 2002 Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high value added drug discovery services, announced today the extension of its original one-year discovery chemistry ... Evotec OAI and MediGene have Identified New Active Compounds for the Treatment of Cardiac Diseases Hamburg, Germany, March 27, 2002 Hamburg | Martinsried, Germany " The biopharmaceutical company MediGene AG (Nmarkt/Frankfurt: MDG) and Evotec OAI (Nmarkt/Frankfurt: EVT), a supplier of integrated high-value-added drug discovery services, have successfully ... Evotec OAI and SiREEN Enter Into A Drug Discovery and Development Agreement To Identify New Small Molecule Therapeutics Hamburg, Germany, March 25, 2002 Hamburg, Germany | Abingdon, UK | Munich, Germany - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high value added drug discovery services, and SiREEN AG, a drug discovery and development company, ... Evotec OAI Successfully Passes First Milestone in Collaboration with Byk Gulden/Altana Hamburg, Germany, March 25, 2002 Hamburg, Germany | Abingdon, UK " Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value-added drug discovery services, announced today that it has successfully completed phase 1 of the ... Evotec OAI AG - 2001 Annual Financial Statements: Continued Strong Progress and an Optimistic Outlook for 2002 Hamburg, Germany, March 25, 2002 Sales increase of 124% to EUR 63.2 million year on year 21% pro-forma growth in drug discovery services Adjusted net loss reduced by 35% to EUR (8.1) million EBITDA of EUR (1) m close to break-even Positive ... Evotec OAI and Ionix Collaborate on Analgesic Drug Discovery Hamburg, Germany, February 5, 2002 Hamburg, Germany | Abingdon, UK " Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value-added drug discovery services, announced today that it has signed an agreement with Ionix ... Evotec OAI and Serono Extend Discovery Chemistry Agreement First compounds resulting from the collaboration progressing into pre-clinical testing. Hamburg, Germany, January 24, 2002 Hamburg, Germany/ Abingdon, UK " Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value-added drug discovery services, announced today a one year, EUR 2.4 million lead optimisation programme ... 2001 Evotec OAI EVOscreen® Mark III Passed Factory Acceptance Testing with GlaxoSmithKline with Excellent Results Hamburg, Germany, December 17, 2001 Hamburg, Germany / Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value added drug discovery services, today announced that its new generation of ultra-high- throughput screening ... Evotec OAI AG Signs Chemical Library Agreement with Merck & Co., Inc. Hamburg, Germany, December 3, 2001 Hamburg, Germany/ Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value-added drug discovery services, announced today that it has entered into an agreement with Merck & ... Third Quarter 2001: Evotec OAI on Track for 2001 Hamburg, Germany, November 8, 2001 Sales increased to EUR 39.6 million Operating loss reduced to EUR (11.9) million Several contracts new or expanded Extraordinary strong Q4 expected Hamburg, Germany / Abingdon, UK - Evotec OAI AG (Neuer Markt: ... Evotec OAI and Byk Gulden/Altana Enter into a Collaboration Hamburg, Germany, October 25, 2001 Hamburg, Germany / Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value added drug discovery services, announced today a contract agreement with Byk Gulden Lomberg Chemische ... Evotec OAI and VitaResc Biotech Extend Collaboration in Anti-Thrombotic Drug Development Hamburg, Germany, October 16, 2001 Martinsried, Hamburg, Germany / Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value added drug discovery services, and VitaResc Biotech AG, Martinsried, Germany, announced today ... Evotec OAI and Rigel Pharmaceuticals Enter Into Medicinal Chemistry Agreement To Identify A New Class of Anti-Cancer Compounds Called Ubiquitin Ligase Inhibitors Hamburg, Germany, October 2, 2001 South San Francisco, California/ Hamburg, Germany/ Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value added drug discovery services, and Rigel Pharmaceuticals Inc., a drug ... Evotec OAI Appoints Dirk Ehlers as Chief Financial Officer Hamburg, Germany, September 11, 2001 Hamburg, Germany/ Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value added drug discovery services, today announced the appointment of Dr Dirk Horst Ehlers to the Chief ... Evotec OAI and Novartis sign licence and technology agreement for on-bead screening Hamburg, Germany, September 4, 2001 Hamburg, Germany/Abingdon, UK - Evotec OAI (EVOTEC BioSystems AG, Neuer Markt: EVT), a provider of high-quality integrated drug discovery services for the pharmaceutical and biotechnology industries, has entered into a licence ... Second Quarter 2001: Evotec OAI Makes Further Good Progress Hamburg, Germany, August 21, 2001 Sales increased significantly to EUR 26.3 million Financials in line with expectations Several contracts new or expanded Healthy cash position of EUR 35.6 million Hamburg, Germany / Abingdon, UK - EVOTEC ... Evotec OAI Extends Combinatorial Chemistry Collaboration with Pharmacia Corporation Hamburg, Germany, August 21, 2001 Hamburg, Germany/Abingdon, UK - Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT), a supplier of integrated high-value added drug discovery services, today announced that it has signed a new four-year contract ... Evotec OAI Announces Appointment of Mark Whittaker as Director of Drug Discovery Hamburg, Germany, August 15, 2001 Hamburg, Germany/ Abingdon, UK - Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT), a supplier of integrated high-value added drug discovery services, today announced that it named Mark Whittaker, D. Phil., to ... Evotec OAI and MelTec form Joint Venture and Enter into a Drug Discovery Service Collaboration Hamburg, Germany, June 18, 2001 Interlocking a Proteomics Target Finding and Validation Machinery with the Industrialised Drug Discovery Process: Evotec OAI and MelTec form Joint Venture and Enter into a Drug Discovery Service Collaboration Hamburg, ... DIREVO Awarded Subsidy by North Rhine-Westphalia Government Hamburg, Germany, June 15, 2001 Hamburg, Germany | Abingdon, UK - DIREVO Biotech AG today announced that it will receive a subsidy of DM 9.8 million from the state government of North Rhine-Westphalia. The money will be used to fund a development ... Evotec OAI Signs a Chemical Library Contract with Roche Hamburg, Germany, June 12, 2001 Hamburg, Germany | Abingdon, UK - Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT) a supplier of high value added biological, chemical and screening services, has signed a one-year contract to supply chemical ... First Quarter 2001: Oxford Asymmetry (OAI) Merger Shows First Results Hamburg, Germany, May 16, 2001 Sales increased by 440% to EUR 11.3 million Financials in line with expectations First joint biology and chemistry contracts signed Strong cash position of EUR 49.2 million Hamburg, Germany / Abingdon, UK - ... Evotec OAI and Serono Sign Assay Development and Screening Services Agreement Hamburg, Germany, April 26, 2001 Hamburg, Germany/ Abingdon, UK/ Geneva, Switzerland - Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT), a supplier of integrated high-value added biological, chemical and screening programmes to the ... EVOTEC OAI: Appointment of new Chief Executive Officer Hamburg, Germany, April 18, 2001 Hamburg, Germany | Abingdon, UK Evotec OAI today announces key management changes following the successful integration of EVOTEC BioSystems AG and Oxford Asymmetry International. With effect from June 30, 2001, ... Evotec OAI Signs Technology Agreement With Celltech Hamburg, Germany, April 10, 2001 Hamburg, Germany | Abingdon, UK - Evotec OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT), a supplier of integrated high-value added biological, chemical and screening services to the pharmaceutical and biotech ... EVOTEC BioSystems AG - 2000 annual financial statements: Dynamic growth together with Oxford Asymmetry International Hamburg, Germany, March 29, 2001 Sales increase by 189% to EUR 28.3 million Integration of Oxford Asymmetry International well advanced Annual results meet analyst forecasts Strong cash position of EUR 49 million First integrated service ... MediGene applies Evotec OAIs leading technologies for the identification of novel drugs to treat cardiovascular diseases Hamburg/Munich, March 28, 2001 Hamburg/Munich, March 28, 2001. MediGene AG (NMarkt: MDG) and EVOTEC BioSystems AG (Evotec OAI) (NMarkt: EVT) announced today, that MediGene, a biopharmaceutical company with a focus on cardiac and cancer therapies, will ... Glaxo SmithKline Accepts EVOTEC OAI's uHTS System EVOscreen® Hamburg, March 7, 2001 All development partners now equipped with EVOTEC OAI's ultra high-throughput screening technology: March 7, 2001 - EVOTEC BioSystems AG (EVOTEC OAI) (Neuer Markt: EVT) today announced that EVOscreen® Mark II, the ... EVOTEC OAI Signs Two Chemistry Services Contracts With Lilly Hamburg, Germany/Abingdon, UK, March 1, 2001 1 March 2001 - EVOTEC OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT), a supplier of integrated high-value added biological, chemical and screening services to the pharmaceutical and biotech industries, has ... EVOTEC OAI Wins Contract for the Supply of Chemical Libraries to Solvay Pharmaceuticals Hamburg, Germany/Abingdon, UK, February 8, 2001 8 February 2001 - EVOTEC OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT), a supplier of integrated high-value added biological, chemical and screening services to the pharmaceutical and biotech industries, ... TOP RSS Twitter LinkedIn EVOTEC @Evotec A new approach to off-the-shelf cancer vaccines - https://t.co/4Re4h5FDGx | Our latest blog details Dendritic Cells… https://t.co/xB7m0D5k8k 02:08 PM - 24 NOVEMBER 2021